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May F. M. Elbanna 
INVESTIGATING THE MECHANISMS OF RESISTANCE TO DUAL PI3K/MTOR 
INHIBITOR IN PIK3CA MUTANT BASAL LIKE BLADDER CANCER 
 
Muscle invasive bladder cancer (MIBC) carries a poor prognosis where 
the overall 5 year survival ranges from 48% to 66%.  To date, targeted therapies, 
except for immune checkpoint inhibitors have not been shown to be effective in 
the management of this disease, where conventional chemotherapy (i.e. 
cisplatin) continues to be the standard of care. Therefore, the challenge lies in 
identifying key molecular events that can predict response to targeted therapies 
and thereby provide patients with maximal clinical benefit.  
Using two MIBC patient derived xenograft models (PDX) that carry 
alterations in PI3K signaling, one of the most dysregulated signaling pathways in 
bladder cancer, we studied determinants of response to PI3K targeted inhibition 
and mechanisms of resistance. 
We found that PIK3CA mutation status as well as tumor subtype (luminal-
like or basal-like) play cooperative role in driving treatment response, where 
PIK3CA E542K mutation in basal-like tumors is associated with resistance to 
PI3K inhibition. Resistance is driven by feedback activation of alternative 
feedback signaling such as RAS-MAPK pathway.  
 
viii 
Based on the mechanistic changes induced upon resistance, we tested 
different drug combinations that can overcome resistance to PI3K targeted 
inhibition. Interestingly, we observed bromodomain inhibition by JQ1 to be the 
most effective strategy to re-sensitize resistant cells to PI3K targeted therapy. 
Overall, this project provides a predictive paradigm of response to PI3K 
targeted inhibition in PIK3CA mutant MIBC and sets the stage for future rational 
clinical trial design.  
                                                                 Roberto Pili, M.D., Co-Chair 
                                                                 Travis Jerde, Ph.D., Co-Chair  
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CHAPTER I. INTRODUCTION 
A. Bladder cancer overview 
Bladder cancer is the fourth most common malignancy in men and the 
eleventh most common in women worldwide with 74000 patients diagnosed with 
the disease in the USA and more than 430000 patients all over the world 
(Howlader, Noone et al. 2012, Kamat, Hahn et al. 2016). Age is the most 
significant risk factor for bladder cancer where median age at diagnosis is ~70 
years(Knowles and Hurst 2015, Malats and Real 2015). There is gender disparity 
in bladder cancer incidence where the male: female ration is 3:1. However, 
women tend to have more advanced disease at diagnosis and worse prognosis 
(Horstmann, Witthuhn et al. 2008, Zhang 2013, Dobruch, Daneshmand et al. 
2016). It is still not well established whether hormonal signaling such as AR 
expression plays a role in this behavior with respect to both incidence as well as 
prognosis(Lombard and Mudryj 2015, Kashiwagi, Ide et al. 2016, Chen, Cui et al. 
2017, Li, Chen et al. 2017).  
 
Genetic predisposition is not obvious in the majority of bladder cancer 
cases. However, genome wide association studies have identified some single-
nucleotide polymorphisms (SNPs) that are associated with increased cancer 
risk(Gu and Wu 2011). Interestingly, candidate genes close to the SNPs include,  
MYC; TP63; prostate stem cell antigen (PSCA); telomerase reverse transcriptase 
(TERT)–CLPTM1-like (CLPTM1L); fibroblast growth factor receptor 3 (FGFR3); 
apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3A 
2 
(APOBEC3A). Many of these genes are well known for their key role in bladder 
cancer pathogenesis 
 
Another key risk factor in this disease is smoking and other forms of 
environmental exposure(Malats and Real 2015). This is probably one of the 
reasons why bladder cancer is in a unique position, where it is only next to 
melanoma and lung cancer in terms of mutation burden(Kim, Akbani et al. 2015).  
 
B. Histological subtypes of bladder cancer 
Bladder cancers are predominantly urothelial carcinomas. Other 
histological types include squamous, adenocarcinoma, micropapillary, small cell 
and plasmacytoid. In regions where the incidence of schistosomiasis is high, 
squamous cell carcinoma is more common, and bladder cancer may be the 
cancer of highest incidence(Reuter 2006). The association between 
schistosomiasis and squamous bladder cancer have been attributed to many 
factors most notably are higher  levels N-nitroso compounds in addition to local 
inflammation induced by the parasitic infestation and higher incidence of host 
DNA damage (Mostafa, Sheweita et al. 1999).   
 
Urothelial carcinomas are divided into two main entities; non muscle 
invasive bladder cancer (NMIBC) which represents around 75% of the cases and 
for which grade is the main prognostic factor. The other entity is muscle invasive 
3 
bladder cancer (MIBC) which represents around 25% of the cases and is mainly 
prognosticated by stage (Kamat, Hahn et al. 2016). 
 
Taking into account, the distinct histological features of both entities and 
the associated molecular events, a two pathway model has been proposed 
(Spruck, Ohneseit et al. 1994, Wu 2005, Zhu, Blenis et al. 2008). This model 
dominated the field for years as the key paradigm describing the key molecular 
events involved in bladder cancer pathogenesis (Knowles and Hurst 2015). 
According to this model, NMIBC and MIBC are two distinct subtypes with a 
distinct natural history, where NMIBC is largely composed of frequently recurring 
low grade papillary tumors that arise from simple hyperplasia and minimal 
dysplasia that are molecularly characterized by loss of heterozygosity (LOH) of 
chromosome 9 and gain of function mutations in fibroblast growth factor receptor 
3 (FGFR3), PIK3CA (which encodes p110α of PI3K) and stromal antigen 2 
(STAG2). On the other hand, MIBC are high grade, non-genetically stable tumors 
that are thought to develop from flat dysplasia and carcinoma in situ (CIS) 
commonly induced by TP53 mutations in addition to chromosome 9 deletions but 
no FGFR3 mutations(Knowles 2008, Knowles and Hurst 2015).  
 
C. Novel Bladder cancer molecular subtypes 
The two pathway model previously described was incapable of explaining 
the great deal of tumor heterogeneity observed with the two main subtypes: 
4 
NMIBC and MIBC. Therefore, a lot of research was focused on identifying a 
better model for understanding bladder cancer pathogenesis.  
 
Bladder cancer was therefore classified into three entities based on the 
standard paradigm of urothelial differentiation(Volkmer, Sahoo et al. 2012). 
Importantly, immune-histochemical staining (IHC) for cytokeratin14 was used to 
determine those distinct subtypes defined as: CK14 high, CK14 intermediate and 
CK14 low. Among those three groups, CK14 high group which was largely 
comprised of basal-like tumors;  had the worst survival irrespective of stage and 
grade (Chan, Espinosa et al. 2009, Volkmer, Sahoo et al. 2012).  
 
Next to the consideration of cell of origin in bladder cancer pathogenesis, 
a more comprehensive effort was focused on identifying key molecular and 
transcriptomic alterations in the disease. Sjödahl et al. (Sjödahl, Lauss et al. 
2012) identified five major subtypes termed urobasal A (UroA), UroB, 
genomically unstable (GU), squamous cell carcinoma-like (SCCL) and ‘infiltrated’ 
(which is highly infiltrated with non-tumor cells). This was subsequently 
supported by three independent groups which focused on MIBC and identified 
similar subtypes, that specially overlapped with respect to the two major 
subtypes; basal like and luminal like  (Sjödahl, Lauss et al. 2012, Choi, Porten et 
al. 2014, Damrauer, Hoadley et al. 2014, Network 2014, Robertson, Kim et al. 
2017).   
 
5 
Luminal MIBCs were found to be enriched for uroplakins, KRT20, ERBB2 
forkhead box A1 (FOXA1; also known as HNF3α), GATA-binding protein 3 
(GATA3), tripartite motif-containing protein 24 (TRIM24) and peroxisome 
proliferator-activated receptor-γ (PPARγ).  Luminal MIBCS were largely of 
papillary morphology and harbored FGFR3 alterations (amplification and/or 
mutation).  
 
On the other hand, basal MIBCs expressed basal markers (KRT5, KRT6, 
KRT14, CD44 and CDH3). They were either of squamous pathology or had a 
high degree of squamous differentiation. In all studies cited(Choi, Porten et al. 
2014, Damrauer, Hoadley et al. 2014, Network 2014, Eriksson, Rovira et al. 
2018), patients with this subtype had the worst prognosis. Transcription factors 
implicated in this subtype were those known to be active in the basal/stem cell 
compartment of the normal urotheilum, including: signal transducer and activator 
of transcription 3 (STAT3), nuclear factor-κΒ (NF-κB), hypoxia-inducible factor 1 
(HIF1) and p63. This finding echoes the preliminary subtype focused studies 
which utilized normal differentiation paradigm of the bladder as guide for bladder 
cancer subtyping.  
 
It is important to note that Damraeur et al. (Damrauer, Hoadley et al. 
2014) proposed a link between the transcription profile of bladder and breast 
cancer subtypes. Interestingly, they also proposed a classifier of 47 genes 
(Base47) that can be applied to stratify tumors according to subtype. However,  
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the clinical utility of this classifier is yet to be determined (Kamat, Hahn et al. 
2016).  
 
D. Molecular alterations in bladder cancer 
D.1.1. Genomic instability and chromosomal alterations 
MIBCs are characterized by high degree of genomic instability and 
chromosomal alterations in comparison to NMIBC. MIBC is known to harbor 
inactivating mutations in genes involved with DNA damage/repair pathway such 
as: excision repair cross-complementation group 2 (ERCC2), ataxia-
telangiectasia mutated (ATM) and Fanconi anaemia complementation group A 
(FANCA). Such alterations in addition to mutations in the cohesin complex which 
is known to play key role in chromosome segregation plays a role in the high 
degree of genomic instability of bladder cancer(Knowles 2008, Knowles and 
Hurst 2015).  
 
Chromosome 9 deletion in MIBC is associated with loss of key tumor 
suppressor genes such as cyclin-dependent kinase inhibitor 2A (CDKN2A; which 
encodes p16 and p14ARF) and CDKN2B (which encodes p15) at 9p21 and 
tuberous sclerosis 1 (TSC1) at 9q34(Platt, Hurst et al. 2009, Sjödahl, Lauss et al. 
2011). TSC1 is part of the TSC1–TSC2 complex which negatively regulates the 
PI3K/mTOR signaling, a key deregulated pathway in bladder cancer. Loss of 
heterozygosity (LOH) of 9p, homozygous deletion of CDKN2A and loss of 
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expression of p16 in NMIBC are predictors of reduced recurrence-free interval 
(Bartoletti, Cai et al. 2007, Ploussard, Dubosq et al. 2010).  
 
D.1.2. Mutation load in bladder cancer and signaling alterations 
As previously stated, the mutation frequency in bladder cancer is only 
exceeded by melanoma and lung cancer which accounts for the immense 
heterogeneity in this disease that cannot be readily explained through the 
molecular two pathway model(Kim, Akbani et al. 2015). While tobacco smoking is 
a very strong environmental risk factor for bladder cancer; a smoking related 
mutation signature has not been found in the disease(Kim, Mouw et al. 2016).  
 
The most frequently mutated pathways in bladder cancer include:  
FGFR signaling alterations (mutations or upregulation) are predominantly 
found in low grade papillary tumors (Ta) with much less frequency in T1 tumors 
and MIBC. Although Ta tumors are generally associated with a good prognosis, 
the presence of FGFR mutations is associated with higher recurrence(Brooks, 
Kilgour et al. 2012, Knowles and Hurst 2015).  
 
PI3K signaling is one of the key pathways that are highly deregulated in 
bladder cancer (Shah, McConkey et al. 2011, Network 2014, Robertson, Kim et 
al. 2017). Aberrant activation of PI3K signaling can occur either indirectly through 
alterations in tyrosine kinases (EGFR/FGFR) or directly through alterations in the 
pathway itself(Knowles, Platt et al. 2009, Platt, Hurst et al. 2009). 
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Aberrant PI3K signaling is driven by activating PIK3CA mutations in 25% 
of bladder cancer cases(Network 2014). The most common PIK3CA activating 
mutations are single amino acid substitutions that occur either in the helical 
domain (HD) (E545K, E542K) or kinase domain (KD) (H1047R)(Knowles, Platt et 
al. 2009, Platt, Hurst et al. 2009). Functional studies have shown different 
mechanisms of activation by helical and kinase domain mutations, where 
H1047R KD mutation is dependent on P85 binding but not on RAS binding for 
the enzymatic activation of PI3K, however the opposite holds true for HD 
mutations (Zhao and Vogt 2008).   
 
Unlike most solid tumors, bladder cancer holds a unique position where 
PIK3CA HD mutations are more common compared to KD mutations; accounting 
for 80% of cases driven by PIK3CA activating mutations(Platt, Hurst et al. 2009, 
Network 2014). In Bladder cancer, the selective pressure for HD mutations is not 
yet understood and therefore a possible role of distinct HD mutations in 
predicting response to PI3K pathway targeted therapy is yet to be determined 
(Knowles, Platt et al. 2009, Platt, Hurst et al. 2009).   
 
Interestingly, in bladder cancer PIK3CA helical domain mutations are not 
exclusively coexistent with RAS mutations; therefore RAS activation cannot 
always explain resistance to therapy targeting this pathway. In some instances, 
double mutations were identified in PIK3CA; one case with a HD and a KD 
domain mutation, and one case with two mutations in the HD domain (E542K 
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E545K); indicating an additive, non-redundant effect of multiple PIK3CA 
mutations in this disease(Sjödahl, Lauss et al. 2011).Other alterations in PI3K 
signaling in bladder cancer involve: LOH in the lipid and protein phosphatase 
PTEN which negatively regulates PI3K and TSC1 mutation(Knowles and Hurst 
2015).  
 
MAPK signaling in bladder cancer, its role in disease pathogenesis and its 
cross talk with other key altered pathways in the disease (i.e. PI3K signaling), are 
still not clear (Knowles and Hurst 2015). 
 
For instance, FGFR3 mutations have been shown to activate MAPK but 
not PI3K signaling in urothelial cells(Di Martino, L'hôte et al. 2009).  This finding 
resonates with the mutual exclusivity of RAS (HRAS or KRAS) and FGFR3 
mutations in bladder cancer. On the other hand, FGFR3 mutation and PIK3CA 
mutation commonly co-occur in NMIBC (Kompier, Lurkin et al. 2010, Juanpere, 
Agell et al. 2012); suggesting a cooperative cross talk between MAPK and PI3K 
pathways.  It is yet to be determined whether the PI3K-MAPK cross talk is 
preferentially activated by distinct PIK3CA mutations in bladder cancer. 
 
E. Epigenetic alterations in bladder cancer 
E.1. Histone modifications and chromatin modifying genes 
The heterogeneity of bladder cancer and the high incidence of mutations 
stresses the importance of taking into account not only the cooperative cross talk 
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between aberrant signaling pathways, but also the possible cooperative role 
between aberrant signaling and epigenetic modifications (Kim, Akbani et al. 
2015). 
 
Epigenetic balance is crucial to orchestrating gene expression and 
therefore plays a key role in development, neoplastic pathogenesis and 
resistance to therapy(Kim, Akbani et al. 2015, Piunti and Shilatifard 2016).  
 
Interestingly, MIBC has the highest incidence of mutations in chromatin 
modifying genes among all tumors (89%)(Gui, Guo et al. 2011).  Loss of function 
mutations in a large number of chromatin modifying genes are highly enriched in 
bladder cancer; most notably are mutations in Lysine Methyltransferase 2D 
(KMT2D)  and Lysine Demethylase 6A (KDM6A) which were interestingly found 
to be mutually exclusive, indicating either redundant downstream effects or a 
synthetically lethal effect of combined loss (Gui, Guo et al. 2011, Network 2014). 
 
Both KMT2D and KDM6A are members of the complex of proteins 
associated with Set1 (COMPASS) family where KMT2D acts as H3K4 methyl 
transferase while KDM6A acts as a H3K27 demethylase. Opposing roles played 
by the members of COMPASS family and members of other epigenetic families 
such as the polycomb repressive complex 1 and 2 (PRC1 and PRC2) maintain 
epigenetic balance(Piunti and Shilatifard 2016). 
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KMT2D (MLL3/4) mono-methylates enhancers at lysine 4 of histone 3 in 
coordination with the demethylation function of KDM6A (UTX) at lysine 27 of 
histone 3 which counteracts the H3K27 me2/3 repressive mark deposited by 
PRC2 and thus possibly favors H3K27 acetylation by histone acetyltransferases 
(HATs) CBP/P300. H3K27 acetylation is thought to induce expression of 
transcriptionally poised genes when added.  However, the role of transcriptional 
co-regulation undertaken by histone methyltransferases (KMT2D) and 
demethylases (KDM6A) in carcinogenesis remains largely unknown (Kim, 
Sharma et al. 2014, Piunti and Shilatifard 2016). 
 
Earlier reports have suggested possible significant prevalence of KMT2D 
mutations in non-papillary high grade bladder cancer as opposed to papillary low 
grade tumors where mutations in demethylases (KDM6A) are more prevalent 
(Gui, Guo et al. 2011, Kim, Akbani et al. 2015, Kamat, Hahn et al. 2016). This 
dichotomy resonates with the mutual exclusivity observed in the TCGA data with 
regard to mutations in those two chromatin modifying genes(Network 2014). 
However, a conclusive relation between KMT2D and KDM6A mutations and 
basal and luminal subtypes of bladder cancer respectively is yet to be 
determined. 
 
Overall, the role of genetically determined phenotypic variation in bladder 
cancer in driving resistance to therapy remains underexplored. It is therefore 
important to understand how mutations in chromatin modifying genes could 
12 
influence bladder carcinogenesis and subsequently influence therapeutic 
response. 
E.2. DNA methylation 
Bladder cancer is known for extensive DNA methylation changes, many of 
which have clinic-pathological associations (Sánchez-Carbayo 2012).  DNA 
methylation pattern is distinct between NMIBC and MIBC (Wolff, Chihara et al. 
2010, Lauss, Aine et al. 2012), where NMIBC is characterized by distinct patterns 
of hypomethylation in non-CpG islands; while MIBC is characterized by 
widespread CpG island hypermethylation. This provides a proof of concept that 
epigenetic alterations in addition to other molecular alterations previously 
discussed play a key role in bladder cancer pathogenesis that has not been 
explained by the simplistic two pathway model. 
 
Interestingly, the distinct DNA methylation pattern is not only characteristic 
of MIBC VS NMIBC, but also related to distinct MIBC subtypes that have recently 
been proposed (i.e. basal VS luminal)(Network 2014). 
 
The dogma is that hypermethylation in promoters is associated with 
silencing of gene expression; on the other hand hypomethylation within gene 
bodies is usually associated with upregulated expression(Lauss, Aine et al. 
2012). Gene body hypomethylation in some tumors such as medulloblastoma 
have been linked to histone H3 lysine 4 (H3K4) trimethylation, a marker of open 
chromatin; that is known to be deposited by KMT2D, an enzyme that is 
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significantly altered in bladder cancer(Knowles and Hurst 2015). This mandates 
further research into the multiple layers of gene regulation at the epigenetic level. 
 
F. Management of bladder cancer 
Patients with NMIBC are mainly managed by trans-urethral tumor 
resection followed by intravesical chemotherapy in low/intermediate risk 
categories or immunotherapy (i.e. Bacillus Calmette-Guerin  (BCG) ) in high risk 
NMIBC(Kamat, Hahn et al. 2016).  BCG is made from a weakened strain of 
Mycobacterium bovis, a vaccine for tuberculosis. Whereas, the standard of care 
in MIBC is comprised of neoadjuvant cisplatin based chemotherapy followed by 
radical cystectomy and bilateral pelvic lymphadenectomy(Kamat, Hahn et al. 
2016). 
 
To date, besides anti PD-1/PD-L1 therapies(Sundararajan and Vogelzang 
2015), specific targeted therapies have not been approved for the management 
of this disease; where conventional platinum-based chemotherapy continues to 
be the standard of care(Leow, Martin-Doyle et al. 2014, Lobo, Mount et al. 2017). 
 
Recently, efforts aimed at improving the understanding of the disease at 
the molecular level have led to a spur in preclinical drug development research 
focused on various significant targets in the disease such as: EGFR, VEGF, 
FGFR, androgen receptor and CD24(Van Kessel, Zuiverloon et al. 2015). 
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Interestingly, EGFR targeted therapy which once failed to show significant 
improvement in patient survival in clinical studies(Philips, Halabi et al. 2009, 
Pruthi, Nielsen et al. 2010, Wong, Litwin et al. 2013) was shown to provide 
significant therapeutic response in basal-like but not luminal-like bladder tumors 
in a recent preclinical study that was informed by the novel genetically guided 
stratification of bladder cancer patients. This was predominantly attributed to 
overexpression of EGFR in basal-like but not luminal-like MIBC (Rebouissou, 
Bernard-Pierrot et al. 2014).  
 
Taken together, this highlights the gap in the bladder cancer field that shall 
benefit from current novel molecular findings which would ultimately improve the 
outlook for targeted therapy in this disease setting. 
 
F.1. PI3K targeted therapy in bladder cancer 
 A recent attempt at comprehensive molecular characterization of bladder 
cancer has identified PI3K pathway as one of the most frequently dysregulated 
signaling pathways in this disease (25% of cases). PIK3CA (HD) mutations are 
the most frequent alterations in this pathway (20% of cases with PI3K pathway 
activation) in comparison to other alterations (i.e. TSC mutations, PTEN 
mutations, AKT amplification) (Network 2014, Robertson, Kim et al. 2017). There 
is also extensive cross talk between PI3K/mTOR signaling and other key 
signaling pathways in bladder cancer such as MAPK and Wnt signaling(Knowles 
and Hurst 2015). Additionally, it has been shown to be involved in resistance to 
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cisplatin-based chemotherapy(Peng, Wang et al. 2010); therefore it is considered 
to be an attractive therapeutic target.  
 
Despite the centrality of this pathway to bladder cancer pathogenesis, few 
trials have investigated the utility of PI3K/mTOR inhibitors in bladder cancer 
management. Most of the existing trials investigated mTOR inhibitor, everolimus. 
Retrospective analysis of everolimus specific responses found a TSC1 
inactivating mutation in most of the responders. This finding stresses the promise 
of PI3K/mTOR targeting agents in the clinic when used in molecularly susceptible 
patients (Iyer, Hanrahan et al. 2012, Seront, Rottey et al. 2012). 
 
It is important however to note that TSC1 inactivating mutations in bladder 
cancer are far less common than PI3KCA HD mutations(Knowles, Platt et al. 
2009, Platt, Hurst et al. 2009). Nonetheless, only two bladder cancer trials have 
been found to utilize novel PI3K inhibitors (Munster, Aggarwal et al. 2015) and 
(NCT01551030) which utilized GSK2126458 (dual PI3K/mTOR inhibitor) and 
BKM120 (PI3K inhibitor) respectively. Therefore, the significance of PIK3CA HD 
mutations in terms of predicting therapeutic response is yet to be determined. 
 
There is indeed anecdotal data that suggest that PIK3CA mutation status 
can predict response to PI3K targeted therapy.  Patients with wide range of solid 
tumors who were treated with PI3K targeted therapy concluded that patients with 
a PIK3CA H1047R mutation had a higher partial response (PR) rate (38% vs. 
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10%; p=0.018) and a trend towards having a longer median progression free 
survival (PFS) (5.7 months vs. 2 months; p=0.06) compared to patients with 
helical PIK3CA mutations treated on the same protocols. On the other hand, 
patients with E542K HD mutations had a trend towards worse PFS compared to 
patients with E545K HD mutations (Janku, Tsimberidou et al. 2011, Janku, 
Wheler et al. 2013). 
 
However, it is important to interpret retrospective data cautiously and to 
take into account the innate tumor heterogeneity that provides another layer of 
complexity and has shown in many studies to play a role in driving response to 
treatment irrespective of mutation status (Guo, Chekaluk et al. 2013). 
 
F.2. Resistance to PI3K targeted therapy 
PI3K/mTOR signaling is involved in highly complex signaling networks in 
both tumorigenic and non-tumorigenic cells which hampered the clinical utility of 
PI3K targeting agents.  Dose limiting toxicities such as stomatitis, noninfectious 
pneumonitis, rash, hyperglycemia, and immunosuppression have been a major 
issue with PI3K targeting agents(Chia, Gandhi et al. 2015). In addition; the 
centrality of this pathway led to resistance through feedback signaling (Brown 
and Toker 2015). 
 
One of the key resistance mechanisms to PI3K targeted inhibition is 
feedback reactivation of PI3K signaling.  Studies have shown that PI3K inhibition 
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is associated with activation of multiple receptor tyrosine kinases in a FOXO-
dependent manner (Chakrabarty, Sánchez et al. 2012). Similarly, mTOR 
inhibition is associated with feedback activation of PI3K signaling through 
stimulations of receptor tyrosine kinases(O'Reilly, Rojo et al. 2006). 
 
Although dual PI3K/mTOR inhibition was proposed in order to overcome 
the previously mentioned mechanisms of resistance that have been reported 
when targeting either PI3K or mTOR separately; it was not optimal. A study has 
reported JAK2/STAT5 activation which promoted feedback AKT activation in the 
context of dual PI3K/mTOR inhibition (Britschgi, Andraos et al. 2012). 
 
Additionally, chronic exposure of a breast cancer cell line to PI3K inhibitor  
GDC-0941 was associated with PIK3CA amplification and therefore feedback 
activation of PI3K signaling (Huw, O'brien et al. 2013). Whether this happens in 
patient treated with PI3K inhibitors is not yet known. However, it has been 
reported that patients treated with mTOR inhibitor everolimus develop mTOR 
mutations that lead to resistance (Wagle, Grabiner et al. 2014). 
 
Another mechanism by which resistance to PI3K targeted inhibition 
develops is the concurrent activation of alternative signaling pathways. It has 
been shown that PI3K inhibition leads to feedback activation of MAPK signaling 
and therefore better therapeutic outcome upon combined MAPK-PI3K inhibition 
(Carracedo, Ma et al. 2008, Serra, Scaltriti et al. 2011). This highlights the 
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importance of understanding the PI3K-MAPK cross talk bladder cancer which is 
not yet well characterized. Similarly, ribosomal S6-Kinase (RSK) has been shown 
to be an alternative signaling route upon PI3K inhibition(Serra, Eichhorn et al. 
2013). 
 
MYC amplification has also been proposed as a mechanism of resistance 
specifically in the context of PIK3CA mutant tumors (Zhu, Blenis et al. 2008, Ilic, 
Utermark et al. 2011, Liu, Cheng et al. 2011, Muellner, Uras et al. 2011, Dey, 
Leyland-Jones et al. 2015) which is important to consider in bladder cancer given 
the high incidence of therapeutic resistance in basal-like bladder cancer where 
MYC is amplified(Choi, Porten et al. 2014). 
 
Recent reports have also shown that MYC-driven resistance to PI3K 
pathway targeted therapy can be epigenetically driven through sustained 
bromodomain (BRD4) binding at chromatin regulatory regions of insulin receptor, 
EGFR family RTKs and MYC driving their expression and thus signaling 
(Stratikopoulos and Parsons 2016). 
 
F.3. Overcoming resistance to PI3K targeted therapy: rational drug combinations 
PI3K driven preclinical models such as genetically engineered mouse 
models or patient derived xenograft models have continuously provided an 
invaluable tool for testing drug combination regimens to develop rational 
treatment strategies that would improve treatment outcomes in the clinic. 
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A wide range of combinations have been proposed to sensitize cancer 
cells to PI3K targeted inhibition. These combinations include: combined 
PI3K/MAPK inhibition(Carracedo, Ma et al. 2008), combined  PI3K/CDK4/6 
inhibition (Bonelli, Digiacomo et al. 2017) and combined targeting of  PI3K 
signaling and DNA damage response (i.e. PARP) in genetically susceptible 
tumors (i.e. BRCA deficient)(Juvekar, Burga et al. 2012). The choice of the 
optimal combination would therefore be dependent on the molecular make up of 
each cancer diagnosis either with respect to site or subtype. 
 
More recently, studies have looked at the possibility of combining PI3K 
inhibitors with bromodomain (BET) inhibitors; an approach that target the 
epigenome in an attempt to have a more global effect. Bromodomain targeting 
has been shown to suppress MYC expression which is either induced upon 
resistance to PI3K targeted therapy (Zhu, Blenis et al. 2008, Ilic, Utermark et al. 
2011, Dey, Leyland-Jones et al. 2015, Stratikopoulos, Dendy et al. 2015) or 
inherently amplified in a subset of tumors (Dey, Leyland-Jones et al. 2015). A 
dual PI3K-BET inhibitor that can overcome resistance to PI3K targeted therapy 
that is usually multi-factorial and therefore difficult to tackle has been developed 
(Stratikopoulos, Dendy et al. 2015, Stratikopoulos and Parsons 2016, Andrews, 
Singh et al. 2017). 
 
 In summary, PI3K signaling is central to bladder cancer pathogenesis 
which poses this pathway as an attractive therapeutic target. However, 
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therapeutic resistance eventually develops. A better understanding of the 
molecular determinants of this resistance in bladder cancer is key to proposing 
rational drug combinations that would ultimately provide a better therapeutic 
outcome for patients. 
 
G. Overview of drugs utilized in this study  
G.1. LY3023414, a novel dual PI3K/mTOR inhibitor 
LY3023414 is a novel imidazoquinolinone based complex designed to 
inhibit class I PI3K isoforms and mTOR kinase potently and selectively in an ATP 
competitive manner (LoRusso 2016, Smith, Mader et al. 2016). The compound 
was tested both in vitro and in vivo using a wide range of cancer cells lines and 
PDX models. 
 
In vitro, LY3023414 was found to inhibit PI3K/mTOR signaling leading to 
G1 cell-cycle arrest and anti-proliferative activity in wide range of cell lines that 
included; PTEN deficient U87MG glioblastoma cell line, breast cancer cell lines 
and mesothelioma cell lines. It is important to note that no obvious correlation 
between LY3023414 sensitivity and any particular aberration known to activate 
the PI3K/AKT/mTOR pathway was detected whether this aberration was 
mutation, amplification or deletion (Smith, Mader et al. 2016). 
 
LY3023414 was tested in combination with standard of care drugs such 
as: cisplatin, docetaxel, doxorubicin, erlotinib, gemcitabine, irinotecan, paclitaxel, 
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pemetrexed, rapamycin, and tamoxifen) and found to have either an additive or 
synergistic effect. The most significant combination effect was observed with 
erlotinib in pancreatic cancer and rapamycin in lung and renal cancer cell lines. 
 
In vivo, LY3023414 showed high bioavailability and efficient modulation of 
downstream targets in the PI3K/mTOR signaling, i.e.  dephosphorylation of AKT, 
S6K, S6RP, and 4E-BP1 for 4 to 6hours. Additional, daily oral administration of 
the drug to mice was associated with an anti-tumor effect in wide range of 
xenograft models tested that represented various tumor pathologies. The anti-
tumor effect observed was thought to be a strong indicator of drug therapeutic 
effect despite non sustained target inhibition (i.e. 4-6 hours). 
 
Currently, LY3023414 is being clinically tested in a phase I first in human 
dose study in patients with advanced cancer (NCT01655225), and phase II 
double blinded, placebo-controlled randomized phase II study of Enzalutamide 
with or without LY3023414 in patients with metastatic castration resistant 
prostate cancer   (NCT02407054).  
 
G.2. LY3214996, a novel ERK1/2 inhibitor 
LY3214996 is a novel highly selective ERK1/2 inhibitor with IC50 in the 
nanomolar range for both ERK1 and ERK2 in biochemical assays. In an ATP 
competitive manner; it has been shown to potently inhibit phospho-RSK1 in 
BRAF and RAS mutant cancer cell lines(Bhagwat, McMillen et al. 2017).  
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In vitro, cells carrying MAPK pathway alterations (BRAF, NRAS or KRAS 
mutation) have been shown to be highly sensitive to LY3214996. In vivo, target 
modulation induced by LY3214996 (inhibition of phospho-p90RSK1), correlated 
with the anti-tumor effect observed in xenograft models with MAPK alterations 
(i.e. BRAF or NRAS mutant melanoma, BRAF or KRAS mutant colorectal, lung 
and pancreatic cancer xenografts or PDX models). Importantly, LY3214996 
showed a significant anti-tumor effect in a model of melanoma where resistance 
to vemurafenib was driven by MAPK reactivation. This finding supports our 
rationale for testing LY3023414 (PI3K inhibitor)-LY3214996 (ERK1/2 inhibitor) 
combination where we found resistance to LY3023414to be partly driven by 
MAPK reactivation.  
 
Interestingly, LY3214996 was previously tested in combination with 
investigational and standard of care drugs (i.e. CDK4/6 inhibitor abemaciclib) and 
was found to be well tolerated and to have a potent anti-tumor effect in wide 
range of human malignancies (particularly KRAS mutant tumors)(Bhagwat, 
McMillen et al. 2017).  
 
LY3214996, is currently in phase I clinical trial (NCT02857270) being 
tested in patients with advanced and metastatic cancers. 
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G.3. (+)-JQ1, a BRD4-directed small-molecule inhibitor (bromodomain inhibitor) 
The bromodomain and extraterminal domain (BET) family of adaptor 
proteins play diverse roles in transcription regulation by RNA polymerase II (Pol 
II) through its members; Brd2, Brd3, Brd4, and Brdt.  Transcription regulation 
carried out by this family of epigenetic readers is done through their ability to 
recognize acetylated lysines on histone tails and other nuclear proteins (Dhalluin, 
Carlson et al. 1999, Filippakopoulos, Qi et al. 2010). 
 
Brd4 is a well characterized member of this family.  Through its interaction 
with TEFb, it regulates transcriptional elongation in conjunction with the 
acetylation state of chromatin (Jang, Mochizuki et al. 2005). Brd4 has also been 
shown to regulate transcription through interaction with alternative histone 
modifiers such as arginine demethylase Jmjd6 and the lysine 
methyltransferaseNsd3 and the SWI/SNF complex(Liu, Ma et al. 2013). 
 
In 2010, (+)-JQ1, a compound with high affinity to the BET family of 
bromodomains (i.e. Brd4) was characterized alongside with I-BET, a similar 
compound developed by an independent group (Filippakopoulos, Qi et al. 2010, 
Nicodeme, Jeffrey et al. 2010) . (+)-JQ1 functions by displacing BET proteins 
(most notably, Brd4) from chromatin and thereby modulating transcription. 
 
The therapeutic rationale for using (+)-JQ1 was first provided by a rare 
tumor known as NUT midline carcinoma which is driven by Brd4-NUT 
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oncoprotein(Filippakopoulos, Qi et al. 2010). In this disease, treatment with (+)-
JQ1 led to the dissociation of Brd4-NUT complex from chromatin, inhibiting tumor 
growth in mice and interestingly inducing terminal squamous cell differentiation in 
a highly undifferentiated tumor. The observed differentiation induced by (+)-JQ1 
treatment stresses the role of epigenetic changes in controlling tumor 
differentiation and therapeutic response. 
 
Therapeutic benefit associated with the use of (+)-JQ1 in models of more 
common malignancies such as hematological malignancies shed the light on 
alternative oncogenic transcriptional programs that can be effectively suppressed 
by BET inhibition, such as MYC and BCL2 expression (Dawson, Prinjha et al. 
2011, Delmore, Issa et al. 2011, Mertz, Conery et al. 2011). 
 
However, it is important to note that transcriptional effects of bromodomain 
inhibitors have been proposed to be context dependent. For example, while (+)-
JQ1 was found to significantly suppress MYC in leukemia cells, this was not the 
case in fibroblasts where (+)-JQ1 has minimal effect on MYC(Zuber, Shi et al. 
2011). 
 
Therefore, it is thought that for (+)-JQ1 to be therapeutically effective, the 
chromatin/epigenetic state of tumor to be treated should be taken into account.  
Brd4 occupancy has been shown to correlate with specific histone acetylation 
marks such as: H4K5, H4K8, H3K9, and H3K27 (Lovén, Hoke et al. 2013). 
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Additionally, tumors where (+)-JQ1 treatment is most effective in suppressing 
MYC  are those where there is high Brd4 occupancy at nearby enhancers 
(Delmore, Issa et al. 2011).  While MYC is expressed ubiquitously in most 
proliferating cell types, the enhancers that regulate this gene are highly cell type 
specific, therefore therapeutic outcome to bromodomain inhibition can be driven 
by different enhancer configurations at the MYC locus (Hnisz, Abraham et al. 
2013). 
 
Bladder cancer is unique in its epigenetic landscape with respect to  DNA 
hypermethylation (Sánchez-Carbayo 2012) observed in advanced basal-like 
tumors in addition to the high load of mutations in chromatin modifying 
genes(Kim, Akbani et al. 2015). This sets bladder cancer as a model where (+)-
JQ1 could be an attractive therapeutic agent. 
 
Additionally, the fact that resistance to PI3K targeted therapy was 
attributed to MYC overexpression (Zhu, Blenis et al. 2008, Liu, Koul et al. 2009, 
Ilic, Utermark et al. 2011, Matkar, Sharma et al. 2015) in a wide range of tumors 
specifically those either driven by PI3KCA mutations or of basal subtype (i.e. 
triple negative breast cancer) provided rationale for testing the ability of (+)-JQ1 
in overcoming resistance induced upon PI3K inhibition(Stratikopoulos, Dendy et 
al. 2015). More recently a dual PI3K-Brd4 inhibitor was developed to be tested 
for that purpose(Andrews, Singh et al. 2017). 
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Overall, it is important to stress that unlike MAPK inhibitors, the allure of 
(+)-JQ1 lies in its ability to modify epigenetically altered transcription that not only 
influence MYC expression but also RTKs in a more  global manner. 
 
H. Summary, Hypothesis and Specific Aims 
Muscle invasive bladder cancer (MIBC) carries a poor prognosis where 
the overall 5 year survival ranges from 48% to 66% (Howlader, Noone et al. 
2012). To date, besides anti PD-1/PD-L1 therapies (Sundararajan and 
Vogelzang 2015), specific targeted therapies have not been approved for the 
management of this disease and conventional platinum-based chemotherapy 
continues to be the standard of care(Leow, Martin-Doyle et al. 2014). Therefore, 
the challenge lies in identifying key molecular events that can constitute new 
targets for therapeutic interventions, and predictors of response to targeted 
therapies, and thereby providing patients with greater clinical benefit. 
 
The PI3K/AKT/mTOR pathway is among the most frequently dysregulated 
pathways in bladder cancer (Knowles, Platt et al. 2009, Platt, Hurst et al. 2009, 
Knowles and Hurst 2015). Our lab has recently established two human patient-
derived xenograft (PDXs) models from bladder cancer (RP-B-01 and RP-B-02). 
The sequencing of these two PDXs has shown that each carries distinct 
activating PIK3CA mutations in the helical domain HD, E542K and E545K, 
respectively). Both PDXs also carry the mutually exclusive mutations in two 
histone modifier genes, KMT2D and KDM6A, respectively. Interestingly, these 
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two models are biologically distinct, where one model displays a basal-like 
phenotype (RP-B-01) while the other is luminal-like (RP-B-02) (Ciamporcero, 
Shen et al. 2016, Wei, Chintala et al. 2016). 
 
We found that therapeutic resistance to dual PI3K/mTOR inhibitors (i.e. 
LY3023414) occurred in the context of the basal like RP-B-01 (E542K mutant) 
but not in the E545K mutant model. In RP-B-01 models, resistance was 
associated with feedback activation of MAPK signaling (ERK phosphorylation) 
and stabilization of MYC. 
 
The oncogenic transformation induced by PI3K HD mutations is known to 
be RAS dependent (Zhao and Vogt 2008). However, it is not yet clear whether 
feedback RAS-MAPK activation induced upon therapeutic resistance is 
preferentially driven in the context of E542K but not the E545K mutations. 
 
The heterogeneity and high mutation burden in bladder cancer (Kim, 
Akbani et al. 2015) should also be taken into account as another layer of 
complexity that can predict therapeutic resistance to PI3K targeted therapy in the 
context of distinct PIK3CA mutations and distinct tumor subtypes. 
 
The overall objective of the proposed study is to fully dissect the 
mechanisms of resistance to PI3K targeted therapy in PI3KCA driven basal-like 
bladder cancer which carries a worse prognosis and to provide a mechanistic 
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rationale for alternative combinatorial treatment strategies that can overcome 
resistance to single agent therapy. 
 
Our central hypothesis (Figure 1) is that sensitivity or resistance to PI3K 
targeted therapy in bladder cancer is genetically and epigenetically driven by 




Figure 1: Proposed mechanism of resistance to dual PI3K/mTOR 
targeted therapy in PIK3CA E542K MUT Bladder cancer. Drug binding to 
the p110 subunit of PI3K is predicted to be less efficient with E542K but 
not E545K mutation leading to feedback MAPK activation which 
eventually leads to stabilization of MYC. This feedback signaling leads to 
resistance and could potentially be overcome either by combining ERK-
PI3K inhibition or using a bromodomain inhibitor JQ1 through the 
suppression of MYC.  
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We tested this hypothesis by pursuing the following Specific Aims: 
 
Specific Aim I: Determine the role of PIK3CA hotspot helical domain mutations 
in predicting response to PI3K pathway targeted therapy 
Based on the differential response to dual PI3K/mTOR inhibitor 
(LY3023414) that we observed in two bladder cancer PDX models (RP-B-01/RP-
B-02) that carry distinct PIK3CA HD mutations (E542K, E545K respectively), We 
tested whether distinct PIK3CA mutations can drive differential proliferative 
potential in isogeneic HEK cells transfected with the mutations of interest. Next, 
we examined the response of PIK3CA transfected HEK cells to treatment both in 
monolayer and 3D culture. We also evaluated whether resistance in PIK3CA 
E542K transfected HEKs was associated with inefficient target modulation 
compared to the PIK3CA E545K transfected cells. Lastly, we tested therapeutic 
response in additional PIK3CA mutant basal like bladder cancer cell lines to 
determine whether treatment response is  function of solely mutation status or 
both mutation and subtype. 
 
Specific Aim II: Investigate the role of activation of RAS-MAPK signaling 
in driving resistance to PI3K targeted therapy in a mutation dependent manner 
Based on the key role of RAS in interacting with PIK3CA HD mutations to 
induce signaling, we tested whether feedback RAS-MAPK signaling is 
preferentially activated in the context of PIK3CA E542K mutation (RP-B-01) but 
not the E542K mutation (RP-B-02). Activation of MAPK signaling in RP-B-01 
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cells was associated with stabilization of MYC. However, this was that the case 
in RP-B-02 cells. Therefore, we subsequently tested multiple drug combinations 
that included LY3023414 with either ERK1/2 inhibitor or bromodomain inhibitor 
(JQ1). The purpose was to identify a therapeutic strategy that can overcome 
resistance to PI3K targeted inhibition in PIK3CA driven basal like bladder cancer. 
An ongoing effort in this project is to screen additional bladder cancer PDX 
models currently under development for PIK3CA mutation status to validate our 
findings with further in vivo studies. 
 
Taken together, this study is translationally important because it will 
enable us to better understand the determinants of response to PI3K pathway 
targeted therapy in bladder cancer. The proposed research is innovative because 
it represents an unprecedented attempt to evaluate the combined role of PIK3CA 
mutational status and cancer subtype in driving therapeutic response. Ultimately,   
this project is intended to pave the way for more mechanistic studies in order to 
achieve a more personalized therapeutic approach in this disease. 
 
I. Dissertation Overview 
This dissertation describes experiments directed towards testing the 
above specific aims. Chapter II discusses the methodology undertaken to carry 
out the proposed studies.  Chapter III presents the genomic characterization of 
two novel bladder cancer PDX models which were found to carry distinct PIK3CA 
HD mutations. It also provides an overview of the in vitro and in vivo experiments 
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that provided preliminary evidence for differential response to PI3K targeted 
inhibition in both models. This sets the stage for testing whether distinct PIK3CA 
HD mutations indeed drive distinct therapeutic response to treatment in Chapter 
IV.  This central hypothesis was tested using isogeneic HEK cells transfected 
with the mutations of interest. Additionally, in Chapter IV, the potential role of 
feedback RAS-MAPK signaling in driving therapeutic resistance is discussed. 
Rational drug combinations based on the predicted mechanisms of resistance 
are discussed. Since subtype-specific therapeutic response is also a point of 
interest in this work, Chapter V discusses detailed characterization of DNA 
methylation profile in RP-B-01 and RP-B-02 (basal and luminal, respectively) and 
how mutations in chromatin modifying genes could play a role in predicting 
response/resistance to PI3K targeted inhibition. Finally Chapter VI discusses the 
major findings and limitations of the study as well as the proposed future 
experiments that are needed to fully dissect the mechanisms of resistance to 
PI3K targeted therapy in PIK3CA mutant bladder cancer.  
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CHAPTER II: MATERIALS AND METHODS 
A. Genomic Profiling of MIBC PDX models (RP-B-01 and RP-B-02) 
A.1. Whole Exome Sequencing 
Individual exome capture of each DNA sample was carried out using the 
SureSelectXT Reagent kit as per manufacturer’s recommendation (Agilent 
Technologies, Inc.). 3 μg of genomic DNA was fragmented to a size range of 
150-200 bp followed by end repair, adaptor ligation, and low cycle (5) PCR. 
Libraries were purified and validated for appropriate size (225-275 bp) on a 2100 
Bioanalyzer High Sensitivity DNA chip (Agilent Technologies, Inc.). 750 ng of 
purified library was then hybridized to the SureSelectXT Human All Exon 50 Mb 
library for 18 hours at 65°C. The captured regions were then bound to 
Streptavidin T1 magnetic beads (Life Technologies, Inc.) and washed to remove 
any non-specific bound products. Eluted library underwent a second 11 cycle 
PCR amplification using Herculase II Fusion Polymerase (Agilent Technologies, 
Inc.) to add sample specific barcodes necessary for multiplexing. Final libraries 
were purified, validated for size by a BioAnalyzer (250-350 bp), and quantitated 
using KAPA qPCR. Individual libraries were pooled (3-plex) in equimolar 2 nM 
final concentration. Each pool was normalized to 10 pM, loaded and clustered to 
individual lanes of a HiSeq Flow Cell using an Illumina cBot (TruSeq PE Cluster 
Kit v3), followed by 2 x 101 PE sequencing on a HiSeq2000 sequencer according 
to the manufacturer’s recommended protocol (Illumina Inc.).  
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A.2. Mutation Detection in Primary tumors 
High quality paired-end reads passing Illumina RTA filter were aligned to 
the NCBI human reference genome (GRCh37) using BWA (Li and Durbin 2009). 
PCR duplicated reads were marked using Picard (Li, Handsaker et al. 2009). 
Putative SNVs and Indels were identified by running variation detection module 
of Bambino(Edmonson, Zhang et al. 2011). All putative SNVs were further 
filtered based on a standard set of criteria to remove the following common types 
of false calls: (1) the alternative allele was present in the matching normal 
sample and the contingency between the tumor and normal samples was not 
statistically significant; (2) the mutant alleles were only present in one stand and 
the strand bias was statistically significant; (3) the putative mutation occurred at a 
site with systematically reduced base quality scores; (4) the reads harboring the 
mutant allele were associated with poor mapping quality. Ambiguous calls were 
manually inspected to ensure accuracy. Putative indels were evaluated by a re-
alignment process to filter out potential false calls introduced by unapparent 
germline events, mapping artifacts and homopolymer. All mutations were 
annotated using ANNOVAR(Wang, Li et al. 2010) with NCBI RefSeq database. 
 
A.3. Mutation Detection in Xenograft Tumors 
To filter out reads caused by mouse stromal contamination in PDX, all 
reads from the PDXs were run through an in silico approach to determine the 
species of origin. More specifically, we first created a combined reference 
sequence containing the sequences of all chromosomes in the NCBI genome 
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assemblies of human (GRCh37) and mouse (GRCm38), and then aligned reads 
from PDX to the combined reference sequence using BWA. Only reads classified 
as human but not mouse origin were kept in downstream analyses. Afterwards, 
standard somatic mutation calling was performed on PDX with the matched 
normal as described previously. For testing purpose, we also performed somatic 
mutation calling on the uncleaned PDX data to evaluate the effect of mouse 
contamination on the somatic mutation calling. 
 
A.4. Comparison of Mutation in Primary versus Xenograft Tumors 
All unique somatic mutations identified from the primary tumor or PDX 
were re-visited in both the primary tumor and matched PDX BAM files. The 
number of mutant and non-mutant reads at the site of each mutation in all BAM 
files was extracted using Mutation Reads Extractor to calculate coverage and 
variant allele fraction (VAF). 
 
A.5. Sanger Validation 
PCR amplicons targeting the PIK3CA and CASP8 regions were generated 
with gene specific primers using a touchdown PCR protocol with the following 
parameters: 94°C for 15 min, followed by 45 cycles of 94°C for 20 seconds, 68°C 
initial annealing for 30 seconds (followed by 1°C reduction of temperate per cycle 
to a final annealing temperature of 58°C for remaining 35 cycles), and 72°C for 1 
min. Amplicons were purified using the QIAquick® PCR Purification Kit (QIAGEN 
Inc., Valencia, CA) as per manufacturer instructions. Ten microliter aliquots for 
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each sample were run on a 2% agarose gel for 1 hour at 100V to confirm the 
correct amplified length (~250 bp). The products were tagged using Big Dye 
Terminator v3.1 Master Mix Kit (Life Technologies™, Carlsbad, CA) as per 
manufacturer instructions, and purified over hydrated Sephadex-G50 from 
Sigma-Aldrich (Sigma-Aldrich®, St. Louis, MO), in Multiscreen HV Plates 
(Thermo Fisher Scientific Inc., Waltham, MA). The eluted samples were placed 
on a 3130xl ABI Prism Genetic Analyzer and run on the default settings for 50 cm 
Array using POP-7 Polymer. The data was analyzed with Sequencing Analysis 
5.2 software (Life Technologies™, Carlsbad, CA). 
 
A.6. RNA-Seq Analysis 
Raw reads that passed quality filter from Illumina RTA were first pre-
processed by using 1) FASTQC for sequencing base quality control and 2) 
cutadapt to remove adapter sequences if applicable. Those reads were then 
mapped to the latest mouse reference genome (mm10) and ENSEMBLE 
annotation database using Tophat (Trapnell, Pachter et al. 2009) or STAR(Dobin, 
Davis et al. 2013). A second round of QC using RSeQC(Wang, Wang et al. 
2012) was applied to mapped bam files to identify potential RNA-Seq library 
preparation problems. From the mapping results, reads that matched a single 
unique location in the genome were kept, allowing up to two mismatches for 
further analysis. The number of reads aligning to each gene was calculated using 
HTSeq(Anders, Pyl et al. 2015). Differentially expressed genes were identified 
using DESeq2 (Love, Huber et al. 2014), a variance-analysis package developed 
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to infer the statically significant difference in RNASeq data. A biological 
hypothesis was also tested using a generalized linear model implemented in 
DESeq2 by construct corresponding contrasts. Multiple testing corrections were 
applied. The list of differentially expressed genes (DEGs) were analyzed for 
enriched Gene Ontology and/or KEGG pathway term with the GAGE (Luo, 
Friedman et al. 2009) Bioconductor package. GSAASeqSP(Xiong, Mukherjee et 
al. 2014) was also applied for pathway analysis that utilizes p-values from all 
genes instead of only DEGs. 
 
B. In-Silico Modeling of PI3K protein and Protein-Drug (LY3023414) interactions 
B.1. Structure Modeling 
The crystallographic structure of the proteins PI3K (E542K MUT/ RP-B-01) 
and PI3K (E545K MUT/ RP-B-02) were not found in the Protein Data Bank (PDB) 
of Research Collaboratory for Structural Bioinformatics (RCSB) (Berman, 
Westbrook et al. 2000).  Hence, the protein structures were modelled for further 
studies. Homology modeling is a very powerful tool for the design of 3D structure 
of a protein. The homology search for the two mutant sequences were performed 
through NCBI BLASTp against PDB database to obtain templates for the 
structure modeling(Johnson, Zaretskaya et al. 2008). The molecular modeling of 
the mutants was performed with MODELLER 9.16 (Fiser and Šali 2003). It 
applies spatial restraints of probability density functions than the energy 
utilization. The python commands were specified to produce five mutant models. 
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The mutant model with minimum DOPE score was chosen as the best model. 
The composed models were approved by SAVES server. 
 
B.2. Ligand 
The structure of the ligand molecule LY3023414 was obtained from 
Chem-IDplus, a TOXNET database maintained by the U.S National Library of 
Medicine (NLM) (Hochstein, Arnesen et al. 2007). LY3023414 is highly soluble at 
pH 2-7. In biochemical testing against approximately 266 kinases, LY3023414 
inhibited class I PI3K isoforms, mTORC1/2, and DNA-PK at low nanomolar 
concentrations. In vitro, inhibition LY3023414 inhibited PI3K signaling resulting in 
G1 cell-cycle arrest and arresting cancer cell proliferation in wide range of cancer 
cell lines. In vivo, LY3023414 was highly bioavailable and was capable of 
inducing dose-dependent transient dephosphorylation of PI3K/AKT/mTOR 
pathway downstream substrates such as AKT, S6K, S6RP, and 4E-BP1 that 
lasted 4-6 hours which is related to the drug half-life of 2 hours. In mice, 
LY3023414 was given either once or twice daily. In both dosing methods, 
antitumor activity was observed despite non sustained target modulation. 
However, the intermittent inhibition of downstream targets was not thoroughly 
addressed and it was not clear whether it can lead to feedback activation or 
resistance in select cancer diagnoses as opposed to others. LY3023414 was 
tested in combination with standard of care drugs such as cisplatin and was 
found to have an additive effect, however a thorough understanding of whether 
this additive effect was influenced by cancer subtype was not addressed. 
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LY3023414 is currently being tested in Phase I and II trials in wide range of 
human malignancies(Smith, Mader et al. 2016). 
 
B.3. Molecular Docking 
The protein-ligand intercommunication was computationally analyzed by 
molecular docking. We have adopted surflex-dock method, Sybyl-X 2.0 (Jain 
2003). This study act as an important platform to explain the significant 
interactions that makes the protein-ligand complex more stable. Before the 
initiation of docking, the mutant proteins PI3K (E542K MUT/ RP-B-01) and PI3K 
(E545K MUT/ RP-B-02) were processed by the standard procedures of surflex-
dock program namely, the elimination of heteroatoms related to the protein, fixing 
of side chain, bumps relaxation and inclusion of hydrogen (H) atoms. The 
AMBER7 F99 force field was used to assign charge and atom types for each 
atom of the protein (Pearlman, Case et al. 1995). The Gasteiger-Huckel charges 
were computed for small molecules. Energy minimization of the protein was 
executed by the conjugate gradient method (Powell’s method) (Fletcher and 
Powell 1963) in association with tripos force field. The protomol was created with 
specific active site residues, where LY3023414 can go and bind. Surflex-dock 
uses an empirical scorings function that discloses the various interaction 
energies involved between protein and ligand (Paulsen and Anderson 2009). The 
scores are Dock score, Chem score, Gold score, Crash score, PMF score, Polar 
score and Consensus score (C-score). This C-score combines all other scores 
(Dock score, Chem score, Gold score, Crash score, PMF score, Polar score) and 
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rank the complex based on the binding energy. The high binding energy 
complexes were identified by their C-score as well as the H-bond formations. All 
the interacting energy values are mentioned in kcal/mol. 
 
B.4. Molecular Dynamic Simulation 
MD simulation was executed to examine the stability of the PI3K E542K 
MUT -LY3023414 and PI3K E545K MUT-LY3023414 complexes after 45000 ps. 
The Gromacs 4.5.5 package was employed for the MD simulation(Hess, Kutzner 
et al. 2008).  The mutant proteins PI3K (E542K MUT/ RP-B-01) and PI3K (E545K 
MUT/ RP-B-02) topology was generated by the Gromacs standard parameters 
along with Gromos96 53a6 force field(Oostenbrink, Villa et al. 2004). Then the 
ligand LY3023414 topology was created by an online PRODRG 
server(SchuÈttelkopf and Van Aalten 2004). The solvation of the system was 
carried out by simple-point-charge models placed in a cubic box(Berendsen, 
Postma et al. 1981). The complexes were located 1.2 nm gap away from the 
cubic box. The total system was made neutral by the addition of Na+ or Cl-. The 
steepest descent algorithm was used for energy minimization for 50000 steps. 
The position restraining of the protein was performed in constant number of 
particles, volume and temperature (NVT) for 100 ps at 300 K and followed by 
simulation in constant number of particles, pressure and temperature (NPT) for 
100 ps at 300K. Linear Constraint Solver algorithm was used to restrain the bond 
length(Hess, Bekker et al. 1997). The electrostatic communications were 
determined by the Particle Mesh Ewald Method (Darden, York et al. 1993). The 
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production simulation was executed for 45000 ps simulation. After the end of the 
simulation, trajectory run was performed and the generated graphs were 
visualized through Xmgrace tool (Turner 2005). 
 
C. In-Vitro Experiments 
C.1. Materials 
DMEM and Ham’s/F-10 media were purchased from Thermo Scientific 
(Waltham, MA, USA). For 3D culture, growth factor reduced. Phenol-red free 
matrigel was purchased from Corning (Corning, NY, USA). Collagen was 
provided by Dr. Sherry Harbin at Purdue University, West Lafayette (Indiana, 
USA). Matrigel based 3D culture was carried out in 96-well Black/Clear Round 
Bottom Ultra Low Attachment Spheroid Microplate (#4515) supplied by Corning 
(Corning, NY, USA). 
 
Immortalized urothelial cells (SV-HUC) were purchased from ATCC. HEK-
293T cells and bladder cancer cell lines (253J and TCCSUP) were provided by 
collaborators at Roswell Park Cancer Institute (Buffalo, NY). Both HEK and SV-
HUC cells were selected for overexpression of PIK3CA. HEK cells are well 
known for being readily transfectable which makes them an invaluable tool for 
testing the function of specific proteins including PI3K (Nakanishi, Walter et al. 
2016). Similarly, we chose SV-HUC cells for being a physiologically relevant cell 
line that we can use to assess the impact of specific PIK3CA mutation in 
bladder/urothelial background. 253J and TCCSUP cell lines were selected for 
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being PIK3CA mutant bladder cancer cell lines (Earl, Rico et al. 2015). All cell 
lines used in this project were grown in DMEM medium containing 10% FBS and 
1% penicillin-streptomycin (pen-strep).  
 
LY3023414 was kindly provided by Eli Lilly and Company. Other drugs 
used in this study (BEZ235, BKM123, LY996 and JQ1) were purchased from 
Selleck Inc (Selleckchem, Houston, TX).  
 
For transfection purpose, HA-PIK3CA wild-type and mutant (E545K) 
(Addgene plasmids 12522, 12525) from Dr. Jean Zhao (Dana-Farber Cancer 
Institute, Boston, MA)(Zhao, Liu et al. 2005) were used. HA-PIK3CA E542K was 
generated by Quick Change site-directed mutagenesis from Agilent Technologies 
(Santa Clara, CA). Following transfection, cells were selected using Puromycin at 
concentration of 2ug/ml for HEK-293T cells and 0.25 ug/ml for urothelial cells.  
 
For Western blotting, monoclonal antibodies against GAPDH, AKT (total 
and P-AKT), mTOR (total and P-mTOR), ERK1/2 (total and P-ERK), PPRAS40, 
P-4EPB1, P-S6, Cleaved PARP, Cleaved Caspase-3, LC3B, HA-tag, c-MYC, 
P110α  were purchased from Cell Signaling (Danvers, MA). For 
Immunohistochemical (IHC) analysis, antibodies against CK20 (Clone Ks20.8) 
and against CK5/6 (Clone D5/16 B4) were purchased from DAKO (Glostrup, 
Denmark). Antibodies against E-cadherin, Vimentin and IHC specific P-mTOR 
were purchased from Cell Signaling (Danvers, MA). Secondary antibodies were 
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from Thermo Fisher Scientific (Pittsburgh, PA, USA). For IHC, DAP was 
purchased from DAKO (Glostrup, Denmark) and Immpress HRP anti-
mouse/rabbit were purchased from vector laboratories (Burlingame, CA).    
 
The Trizol, TaqMan probes, and qPCR master mix were procured from 
Life Technologies (Carlsbad, CA). The iScript reverse transcriptase was from 
Bio-Rad (Hercules, CA). 
 
C.2. Isolation and Propagation of cells from PDX tumors 
RP-B-01 and RP-B-02 cells were isolated from MIBC PDX tumors 
developed from original patient tumors by subcutaneous implantation in SCID 
mice. Cells were authenticated by chromosome karyotyping (Ciamporcero, Shen 
et al. 2016). Cells were cultured using enriched F-medium (2:1 mixture of 
Ham’s/F-10 medium and DMEM medium) supplemented with ROCK inhibitor and 
insulin growth factor as described previously(Liu, Ory et al. 2012). These cells 
were confirmed to be of human origin with the detection of the human specific 
Alu gene by RT-PCR. 
 
C.3. Cell Proliferation and Metabolic activity assays 
The proliferation of cells with and without addition of drugs was monitored 
either by crystal violet staining, an alamarBlue based fluorescence assay or MTT 
absorbance assay. Either urothelial cells or HEK293-T cells were used. For 
urothelial cells, 4000 cells in 100 µL growth medium were incubated in 96-well 
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clear bottom black plates for 24 hours followed by incubation with different drug 
concentrations (range: 60 nM to 2 µM) at different time points ranging from 48 to 
96 hours. For HEK293-T cells 1000 cells were seeded in 100 µL growth medium.  
At the end of incubation, 10 µL of alamarBlue reagent (AbD Serotec, Kidlington, 
UK) was added and after overnight incubation, fluorescence readings were taken 
at excitation and emission wavelengths of 544 nm and 590 nm respectively. If 
MTT was used, 20 µL of MTT reagent (Biovision, Milpitas, CA) was added and 
after 4 hour incubation, wells were washed, 100 µL of methanol was added/well 
and absorbace was measured at 570 nm. Data were analyzed and dose 
response curves generated using GraphPad Prism software (v. 7.0).  
 
C.4. Three Dimensional growth assays 
Three dimensional (3D) growth assay was adapted based on a previously 
described method used from pancreatic cancer cell lines(Arpin, Mac et al. 2016). 
Briefly, bladder cancer cells (RP-B-01, RP-B-02, TCCSUP, 253J) and PIK3CA 
transfected HEK293-T cells were resuspended in DMEM media containing 3% 
Matrigel (Corning, NY) at a cell density of 2000 cell/well and plated in 75 µL of 
Matrigel containing media in 96-well round bottom ultra low attachment spheroid 
microplates (Corning #4515). Cells were treated on days 4 and 8 following 
establishment of 3D spheres. alamarBlue based fluorescence assay was used 
for quantification as previously described. Alternatively, cells were made stably 
fluorescent by TdTomato or GFP via lentivirus and gowth/drug response was 
quantified using Thermo ArrayScan high-content imaging system. Images of 3D 
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structures were captured by ArrayScan using a 2.5× objective for either 
TdTomato or GFP; then two-dimensional (2D) projections were processed to 
quantify differences in total intensity and total area.  At least 3 repeats of cell 
proliferation were carried out for each cell line both in monolayer and in 3D to 
monitor proliferation over time and differential drug response in vitro.   
 
C.5. Western Blot analysis 
Protein extracts were isolated from tumor tissue using a polytron 
homogenizer and cells were extracted by sonication in lysis RIPA buffer 
(Biovision, Milpitas, CA) supplemented with phosphatase and protease inhibitors. 
Forty micrograms of protein were separated by gel electrophoresis followed by 
transfer on to a nitrocellulose membrane. Western blot analysis was performed 
using the primary antibodies previously described by overnight incubation of 
membranes in 4°C at 1:1000 dilution. All dilutions were made in Tris Buffered 
Saline-0.05% Tween-20 buffer containing 5% bovine serum albumin (BSA).Next, 
membranes were probed with secondary HRP conjugated antibody (rabbit or 
mouse) and incubated for 1 hour at room temperature at 1:5000 dilution. 
 
C.6. Immuno-histochemical (IHC) analysis 
I used IHC analysis to determine the expression of various molecular 
markers in the original cystectomy specimens in comparison to their PDX 
counterparts (RP-B-01 and RP-B-02). Standard immunohistochemical protocols 
were followed as previously described by our lab (Ciamporcero, Shen et al. 2016, 
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Wei, Chintala et al. 2016).  Briefly, formalin fixed paraffin embedded tumors were 
used to prepare (5 μm) sections. Sections were deparaffinized followed by 
rehydration and antigen unmasking in sodium citrate buffer (pH 6.0) for all 
antibodies used in IHC experiments except for CK20 and CK5/6 where EDTA 
buffer (pH 8.0) was used. Primary antibodies p-AKT, IHC specific p-mTOR, and 
cytokeratin 5/6/20 were applied to sections overnight at 4°C,  followed by their 
respective horseradish-conjugated secondary antibody (Immpress HRP anti-
mouse/rabbit vector laboratories (Burlingame, CA)) for 1hr at room temperature. 
Photomicrographs were captured using a Zeiss Axio (Peabody, MA) microscope. 
 
C.7. Quantitative RT-PCR 
Gene expression at the mRNA level was determined by performing 
quantitative RT-PCR (qRT-PCR). Trizol reagent was used to isolate RNA from 
tumor tissue and cells. cDNA was prepared using the high efficiency iScript 
cDNA synthesis kit from Bio-Rad (Hercules, CA). Gene specific primers were 
designed in Primer3 software(Rozen and Skaletsky 2000) then utilized to 
determine gene specific expression levels using a SYBR Green PCR Master Mix 
from Bio-Rad (Hercules, CA). CFX96 Touch Real-Time PCR Detection system 
(Bio-Rad) was used for quantification of gene amplification peaks. GAPDH was 
used as an internal control. Normalized fold expression of genes was determined 
using the CFX Manager Software utilizing the ΔΔCt method. 
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C.8. In-Vitro Testing of Drug Combination Synergy 
The growth/metabolic activity of bladder cancer cell lines used was 
monitored by an alamarBlue fluorescence assay as described previously. Cells 
seeded at density of 4000 cells in 100 µL of DMEM media were treated with 
single agent or combination treatment at different concentrations ranging from 
(60 nM to 2 µM). 48 hour post incubation with drugs, 10 µL of alamarBlue was 
added. After overnight incubation with alamarBlue, growth inhibition was 
determined by measuring fluorescence using a Synergy™ H1 plate reader 
(Biotek, Winooski, VT) with excitation and emission wavelengths of 544 nm and 
590 nm respectively. 
 
Fluorescence readings were used to determine the fraction of cells 
affected under each treatment condition.  Fraction affected was plugged in 
Compusyn™ Software to generate isobologram and determine the combination 
index for each combination tested based on the mathematical model developed 
by Chou and Talalay (Chou 2010, Leow, Martin-Doyle et al. 2014). 
 
D. In-Vivo Experiments 
Two patient derived tumor xenografts (PDXs), RP-B-01 and RP-B-02, 
were generated by subcutaneous implantation of fresh primary tumors from 
bladder cancer patients in SCID mice (Ciamporcero, Shen et al. 2016). RP-B-01 
was developed from a treatment naïve female patient diagnosed with T4b N1 Mx 
tumor. The tumor was grade III, infiltrating urothelial carcinoma with 98% 
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squamous differentiation.  On the other hand, RP-B-02 was developed from a 
female patient who received cisplatin based neoadjuvant chemotherapy. The 
tumor was diagnosed as T2b N0 Mx, grade III tumor with squamous 
differentiation. 
 
For evaluation of tumor drug response in vivo, small pieces of PDXs were 
subcutaneously implanted in SCID mice and allowed to establish.  When the 
tumors reached approximately 100-200 mm3, mice were randomized into groups 
of 5-8 mice and treated with either vehicle or LY3023414 (10 mg/kg BID by oral 
gavage). Tumor sizes were blindly measured weekly along with the body weight 
of mice. At the end of the treatment, tumors were collected, weighed, and 
processed for formalin fixation and small pieces were frozen for protein 
extraction. 
 
E. Statistical Analysis 
Statistical analyses were performed with GraphPad Prism 7 software. For 
the continuous outcomes such as tumor growth, I performed the two-sample t-
test for two-arm comparison and analysis of variance (ANOVA) for multiple-arm 
comparison. When ANOVA is used, the ad hoc Tukey test followed to determine 
the mean differences of interest. The assumption of normality was checked using 
histograms and normal probability plot. When normality was questionable, the 
non-parametric Wilcoxon rank test was used. Two-sided P values < 0.05 were 
considered statistically significant. 
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CHAPTER III: DIFFERENTIAL RESPONSE TO A DUAL PI3K/MTOR 
INHIBITOR IN PI3KCA MUTANT UROTHELIAL CANCER 
A. Chapter Summary 
Genomic profiling of different tumor subtypes is increasingly used in order 
to identify valid therapeutic targets and improve outcome for patients. In our lab, 
we developed two muscle invasive bladder cancer (MIBC) patient-derived 
xenograft   (PDX) models; RP-B-01 and RP-B-02. We used genomic profiling 
(whole exome sequencing and RNA sequencing) to characterize both 
models(Wei, Chintala et al. 2016). Based on a newly proposed RNA-Seq based 
molecular classification of MIBC (Choi, Porten et al. 2014, Damrauer, Hoadley et 
al. 2014, Network 2014), we found that each model belongs to a biologically 
distinct subtype, where RP-B-01 was basal like; while RP-B-02 was luminal like. 
We found RP-B-01 to be enriched in cisplatin resistance markers; which include 
Caspase 8 truncating mutation and over expression of cysteine transporter xCT. 
Indeed, we found RP-B-01 to be significantly resistant to cisplatin compared to 
RP-B-02 both in vitro and in vivo.  
Genomic analysis also revealed that both RP-B-01 and RP-B-02 carry 
PIK3CA helical domain (HD) mutations; E542K and E545K respectively. Despite 
the biological similarity between the two PIK3CA HD mutations; the two models 
respond differently to multiple dual PI3K/mTOR inhibitors (i.e. LY3023414) in vivo 
as well as in vitro; where RP-B-02 is responsive while RP-B-01 is resistant. 
Preliminary in silico analysis of drug (LY3023414) binding to each mutation 
revealed more potent binding in the context of the E545K mutation which could 
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potentially lead to the better therapeutic response that we have observed in the 
RP-B-02 model. This finding provided the rational for testing the role of distinct 
PIK3CA HD mutation in determining response to PI3K targeted therapy. Overall, 
we found that while genomic profiling was predictive of therapeutic response to 
cisplatin; the mutation status of PIK3CA was not predictive of response to PI3K 
targeted therapy. This suggests that comprehensive profiling in the context of 
newly characterized bladder cancer subtypes (Basal; Luminal), rather than solely 
mutational analysis, may predict response to PI3K/mTOR targeted therapies in 
bladder cancer. Importantly; this sets the stage for dissecting the role of distinct 
mutations in predicting therapeutic response as well as understanding the 
complex role of alternative pathways and epigenetic changes in driving response 
to treatment.  
 
B. Background and Rationale 
Bladder cancer is the 4th most common malignancy in men and the 9th 
most common in women, with 81,190 new cases and 17,240 deaths expected in 
2018 (Siegel, Miller et al. 2018). Muscle invasive bladder cancer (MIBC) carries a 
poor prognosis where the overall 5 year survival ranges from 35% to 70% 
(Siegel, Miller et al. 2018). To date, besides anti PD-1/PD-L1 therapies 
(Sundararajan and Vogelzang 2015), specific targeted therapies have not been 
approved for the management of this disease, where conventional platinum-
based chemotherapy continues to be the standard of care (Leow, Martin-Doyle et 
al. 2014). However, patients eventually develop cisplatin resistance(Galluzzi, 
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Senovilla et al. 2012, Drayton, Dudziec et al. 2014), thus there is a dire need to 
develop novel therapeutic options for those patients. 
 
PI3K/mTOR signaling is altered in 40% of bladder cancer cases (Network 
2014). However, targeting this pathway bladder cancer patients has not been 
successful so far either due to the toxicity encountered in heavily treated patients 
who usually receive PI3K targeted therapy on clinical trials or due to lack of 
responsiveness (Carneiro, Meeks et al. 2015, Houédé and Pourquier 2015). 
Interestingly however, in a phase II clinical trial where patients were treated with 
everolimus; only patients with mutation in Tuberous Sclerosis Complex 1 (TSC1) 
showed significant response to treatment compared to other patients (Seront, 
Rottey et al. 2012), which highlights the importance of patient selection in clinical 
trial design in order to achieve therapeutic benefit. It is important to point out that 
most of the conducted clinical trials so far are focused on mTOR targeting agents 
(i.e. Everolimus), including a currently ongoing trial at Indiana University 
(NCT01215136). Only two trials are testing agents that target other factors in the 
PI3K/mTOR pathway; one of them is using a dual PI3K/mTOR inhibitor 
(GSK2126458) and the other is investigating the specific PI3K inhibitor buparlisib 
(BKM-120) in metastatic transitional cell carcinoma of the urothelium 
(NCT01551030).  Therefore; So far, a correlation between PIK3CA helical 
domain mutation status and response to treatment has not been determined.  
 
52 
More clinically and molecularly relevant models are necessary to better 
understand the molecular alterations associated with drug response, and to 
develop more effective personalized therapies for MIBC. Patient derived tumor 
xenografts (PDX) have become an increasingly attractive  model for preclinical 
drug development because of their retained original tumor heterogeneity and 
genetic make- up, suggesting a more reliable drug development tool as 
compared to tumor cell lines(Bernardo, Costa et al. 2014, Cirone, Andresen et al. 
2014). To date, there are a limited number of established bladder cancer PDX 
models that are molecularly characterized and available for testing drug 
resistance and sensitivity (Pan, Zhang et al. 2015, Inoue, Terada et al. 2017, 
Suh, Jeong et al. 2017).  
 
In this study, we characterized two PDX tumors recently established in our 
lab by genomic profiling. As previously reported, RP-B-01 is less cisplatin 
responsive as compared to RP-B-02 (Ciamporcero, Shen et al. 2016), and 
carries specific cisplatin resistance markers, such as a caspase 8 mutation and 
over expression of the cystine transporter xCT. Genomic analysis also revealed 
that both RP-B-01 and RP-B-02 carry PIK3CA HD mutations; E542K and E545K 
respectively. However, the RP-B-0-1 has been found to be significantly resistant 
to treatment with dual PI3K/mTOR inhibitor LY3023414 (LY414) suggesting the 
presence of alternative resistance pathways that warrant further investigation.  
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C. Results 
C.1. Genomic profiling of two MIBC PDX models (RP-B-01/RP-B-02) 
In our lab, we developed two MIBC PDX models (RP-B-01 and RP-B-02) 
from two female patients undergoing cystectomy for urothelial carcinoma by 
subcutaneous implantation of tumors pieces from cystectomy specimens in SCID 
mice (Table 1, Page 85) (Ciamporcero, Shen et al. 2016). In order to create a 
predictive model for response to cisplatin (mainstay of therapy in bladder cancer) 
as well as elucidate alternative targeted therapies; we decided to perform 
genomic profiling of the original tumors and the derived PDXs. Using a high 
throughput paired-end sequencing approach, we generated 84 to 330 million of 
100-bp reads per sample. For non-PDX samples, over 98% of the reads were 
successfully mapped to the human reference by using BWA. For PDX samples, 
the mapping rates were 94.5% and 86.6% with human reference. After mapping 
to the human and mouse combined reference, the mapping rates for these two 
PDXs increased to 99.1% and 99.2%. All samples reached the designed goal of 





Figure 2: Effects of mouse contamination on somatic mutation in MIBC 
PDX models. Before (“Uncleaned”) and after (“Cleaned”) filtering out 
mouse contamination, the initial single nucleotide variation (SNV) calls 
from PDX samples (green) were compared with the matched primary 
tumor (blue). Top: “Uncleaned”, bottom: “Cleaned”; Left: RP-B-01, right: 
RP-B-02. The excessive amount of SNV calls in the “Uncleaned” PDX 
data likely reflects artifacts introduced by mouse contamination. A 




Figure 3: Variant allele fraction in primary tumor and matched PDX. 
Variant allele fraction (VAF) defined as the fraction of reads harboring 
mutant allele for each mutation in the primary tumor and matched PDX. 
The mutations with less than 20X coverage in primary or PDX tumor are 
highlighted in red. A previous version of this figure was published in 
(Wei, Chintala et al. 2016). 
 
In a test run on the unfiltered data, we identified 4,276 and 16,861 SNVs 
in RP-B-01 and RP-B-02 respectively (Figure 2). The majority of these SNVs was 
not identified in the primary tumor and was likely caused by mouse 
contamination. After filtering out mouse reads, most of these suspicious mutation 
calls disappeared and the remaining mutations were highly consistent with the 
matched primary tumor. 
 
Following sequencing, we identified 1,008 SNVs and five Indels from the 
primary and PDX in RP-B-01 and 1,101 SNVs and 14 Indels from RP-B-02. The 
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identified mutations were then manually reviewed to ensure accuracy. After 
manual review, there were 919 mutations (917 SNVs and 2 Indels) left in RP-B-
01 and 980 mutations (973 SNVs and 7 Indels) in RP-B-02. The mutation profiles 
were compared between the primary and PDX to determine similarity. In both 
cases, majority (91% in RP-B-01 and 82% in RP-B-02) of all mutations was 
shared by primary and PDX samples (Figure 3). There also existed smaller 
numbers of sample-specific mutations (2% primary-unique and 7% PDX-unique 
in RP-B-01, 3% primary-unique and 15% PDX-unique in RP-B-02), which may 
reflect the tumor progression from primary to PDX tumors. In RP-B-01, the 
frequency of variant alleles (VAFs) of the shared mutations were centered near 
primary = 0.25 and PDX = 0.5, which may indicate higher tumor purity in PDX 
than the primary tumor. Similarly, in RP-B-02, most shared mutations were 
around primary= 0.25 and PDX = 0.5. Additionally, there was a small group of 
mutations near primary = 0.4 and PDX = 1.0, which were likely to be 
homozygous in the PDX (Figure 3). Of note, VAF=1.0 is indicative of 2 alleles 
being mutant (i.e. homozygous mutation) while VAF=0.5 is indicative of one allele 
being mutant (i.e. heterozygous mutation). Along with tumor evolution as well as 
subsequent tumor passaging in mice VAF can change for each mutation. 
 
Among the identified somatic mutations, 13 alterations were previously 
found clinically relevant according to ClinVar or mutated in other cancers as 
summarized by COSMIC (Figure3, Table 1). Most of these mutations were 
present in both primary and PDXs except for CFTR R1066C, which was only 
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present in the PDX. For other novel nonsynonymous mutations, 57 mutations 
occurred in Cancer Gene Census genes or other genes known to be recurrently 
mutated in bladder cancer genes (Morrison, Liu et al. 2014, Network 2014), 
including 10 predicted loss-of-function mutations summarized in Table 1. The 
majority (55/57) of these potentially loss of function mutations were present in 
both the primary and PDX. Only two mutations, RANBP2 P1380R in RP-B-01, 





Table 1: Somatic Mutations identified in RP-B-01 and RP-B-02 
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C.2. MIBC patient-derived xenografts recapitulate original tumors biology 
 
In addition to using genomic profiling in order to confirm the similarity 
between primary tumors derived from cystectomy specimens (Table 2: Patient 
characteristics) and PDX tumors; I used standard histological techniques in order 
to confirm that PDX tumors phenocopied the original tumors. 
 
Hematoxylin and eosin staining (Figure 4) demonstrated that PDX tumors 
maintained similar morphology to original tumors. Immunohistochemical (IHC) 
staining for both E-cadherin and Vimentin (Figure 5) showed that both PDX 
models maintained the epithelial phenotype of original tumors. This confirms our 





























Table 2: Characteristics of primary patient tumors 
60 
models as valid tools for preclinical drug development that can faithfully 
recapitulate the complexity and heterogeneity of patient tumors. 
 
Recently, a novel classification (W. Choi et al., 2014; Damrauer et al., 
2014; Network, 2014) has been introduced in the bladder cancer field in an 
attempt to better stratify the disease into distinct subtypes which would ultimately 
revolutionize bladder cancer therapy into a more personalized approach. Using, 
IHC staining for cytokeratin 5/6 (CK 5/6) and cytokeratin 20 (CK 20); I found RP-
B-01 to express CK 5/6 while RP-B-02 expressed mainly CK 20 (Figure 5). This 
staining pattern confirms distinct subtypes; where RP-B-01 is basal-like while 
RP-B-02 is luminal-like. Importantly, we validated this with gene expression 
analysis which showed basal-like genes to be upregulated in RP-B-01 compared 
to RP-B-02; while luminal-like genes were significantly upregulated in RP-B-02 





Figure 4: Patient derived bladder xenograft models. Xenografts 
established from two different patient tumor samples phenocopy the 
original tumors when observed by H&E. RP-B-01 and RP-B-02 are 
classified as high grade tumors with squamous differentiation. A 
previous version of this figure was published in (Ciamporcero, Shen 
et al. 2016). 
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Figure 5: Characterization of MIBC PDX tumors. Representative 
IHC staining for both E-cadherin and Vimentin show that both 
models maintain an epithelial phenotype similar to original patient 
tumors. Left panel shows representative images of original 
cystectomy specimens and right panel shows representative images 
of PDX tumors. White arrows point to E-Cadherin staining while 




Figure 6:  MIBC PDX models (RP-B-01) and (RP-B-02) are of 
distinct subtype. IHC staining of both models showing RP-B-01 to 
be positive for CK 5/6 and negative for CK 20 indicating a basal-
like phenotype. RP-B-02 is positive for both CK 5/6 and CK 20 
indicating a luminal-like phenotype. A previous version of this 




















Figure 7: Gene expression analysis support distinct subtypes.  
Genes associated with basal-like phenotype (per TCGA data) are 
significantly upregulated in RP-B-01 compared to RP-B-02 (i.e. 
TP63: The master regulator of the basal-like phenotype. Genes 
associated with luminal-like phenotype are significantly upregulated 
in RP-B-02 compared to RP-B-01 (i.e. PPARG, The master regulator 
of the luminal like phenotype) (Choi, Porten et al. 2014).  
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C.3. MIBC patient derived xenografts (RP-B-01&RP-B-02) respond differently to 
a dual PI3K/mTOR inhibitor LY3023414 in vivo   
Aberrant PI3K signaling (Figure 8) is driven by activating PIK3CA 
mutations in 25% of bladder cancer cases (Network 2014). The most common 
PIK3CA activating mutations are single amino acid substitutions that occur either 
in the helical (E545K, E542K) or kinase domain (H1047R) (Zhao and Vogt 2008). 
Unlike most solid tumors, bladder cancer holds a unique position where PIK3CA 
HD mutations are more common compared to KD mutations; accounting for 80% 
of cases driven by PIK3CA activating mutations (Network 2014). Interestingly, 
through comprehensive genomic profiling, we found our bladder PDX models to 
carry distinct PIK3CA HD mutations; where RP-B-01 was E542K mutant, while 
RP-B-02 was E545K mutant. Based on this finding, I tested the response of 
those two models to dual PI3K /mTOR inhibitor in vivo. Interestingly, I found the 
RP-B-02 model to be significantly sensitive to treatment; while RP-B-01 was 
resistant (Figure 9, 10).  
 
Importantly; the anti-tumor effect observed in RP-B-02 was associated 
with inhibition of downstream PI3K/mTOR signaling (i.e. P-AKT &P-S6). 
However, in RP-B-01, I observed upregulation of AKT phosphorylation that 






Figure 8: PI3K Signaling Pathway. The PI3K/AKT signaling pathway 
is activated by receptor tyrosine kinases such as (EGFR. IR), 
integrins, B and T cell receptors, cytokine receptors, G-protein-
coupled receptors and other stimuli that induce the transformation of 
phosphatidylinositol di phosphate (PIP2) into  (3,4,5) trisphosphates 
(PIP3) by phosphoinositide 3-kinase (PI3K). These lipids serve as 
plasma membrane docking sites for proteins that harbor pleckstrin- 
homology (PH) domains (i.e. AKT). At the membrane PDK1 
phosphorylates AKT at Thr308 leading to partial activation of AKT, 
which is then fully activated by being phosphorylated at Ser473 by the 
















Figure 9: Differential response of PIK3CA mutated RP-B-01 and 
RP-B-02 to LY3023414. RP-B-01 (PIK3CA E542K MUT) is not 
sensitive to LY414. Top panel shows tumor volume blindly 
measured throughout treatment. Lower panel shows tumor weight 
blindly measured at the end of treatment (EOT). A previous version 
of this figure was published in (Wei, Chintala et al. 2016) . 




Figure 10: Differential response of PIK3CA mutated RP-B-01 and RP-
B-02 to LY3023414. RP-B-02 (PIK3CA E545K MUT) is sensitive to 
LY414. Top panel shows tumor volume blindly measured throughout 
treatment. Lower panel shows tumor weight blindly measured at the 
end of treatment (EOT). A previous version of this figure was published 










Figure 11: Resistance to LY3023414 in RP-B-01 is associated with 
feedback activation of AKT signaling in vivo. A. In RP-B-01, 
activation of AKT phosphorylation and absence of p-S6 inhibition in 
LY3023414 treated tumors compared to vehicle control. B. RP-B-02 
treated tumors demonstrate inhibition of downstream targets (p-AKT, 
p-S6, p-4EBP1) compared to mice treated with vehicle control. A 
previous version of this figure was published in (Wei, Chintala et al. 
2016).  
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C.4. Isolation and characterization of PDX derived cell lines 
In our lab, we were able to isolate epithelial cells from PDX tumors 
(Figures 9,10)  and subculture them on plastic using growth factor enriched 
media in addition to a feeder system of 3T3 irradiated fibroblasts (Liu, Ory et al. 
2012). Cell lines derived from PDX tumors were morphologically distinct both in 
2D and 3D culture reflecting the morphological differences between those two 
tumors (Figure 12, 13).  Interestingly, I observed that cells growing on plastic 
underwent epithelial to mesenchymal transition. Using western blotting, I was 
able to show that e-cadherin expression was lost and cells started to express 
vimentin (Figure 14). When cells were cultured in 3D, they re-expressed E-
cadherin similar to what we observed in original PDX tumors (Figure 15). 
Therefore; we considered our 3D culture model to be more representative of 









Figure 12: Isolation and characterization of PDX derived cell lines. A. 
epithelial cells from PDX tumors were isolated and propagated in vitro 
(Liu, Ory et al. 2012) Cell lines derived from PDX indicate difference in 
morphology between the two models. RP-B-01 appears to be flatter as 
compared to RP-B-02. B. Proliferation assay shows that RP-B-02 cell 
line grows slower compared to RP-B-01. A previous version of this 


















Figure 13: PDX derived cell lines are morphologically distinct in 
3D culture.  In  media supplemented with 3% growth factor 
reduced matrigel, RP-B-01 cells (Top panel) form less coherent 




Figure 14: Epithelial-mesenchymal (EMT) transition in PDX derived 
cell lines. Western blot showing EMT in PDX derived cells compared 
to original tumors. Transplanting (RP-B-01) cells back in the mouse 

















Figure 15: Re-expression of E-cadherin in  3D model of RP-B-02 PDX-
derived cell line. RP-B-02 cells in 3D culture re-express E-Cadherin (red) 
and are more representative of the original tumor epithelial phenotype.   
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C.5. PDX derived cell lines (RP-B-01&RP-B-02) corroborate the in vivo response 
to LY3023414 in vitro 
Based on the differential response to dual PI3K/mTOR inhibitor 
(LY3023414) that we observed when testing drug response for each model in 
vivo; I hypothesized that a similar response shall be observed in vitro. 
Interestingly however, when I tested drug response in growth factor enriched 
media that we used to isolate the cells, I was not able to see the differential drug 
response that I observed in vivo. When I switched to treatment in regular DMEM 
media I was able to observe a therapeutic response that corroborates our in vivo 
data; where RP-B-01 cells were significantly resistant to LY3023414 compared to 
RP-B-02. The IC50 for RP-B-01 was more than 3- fold the IC50 for RP-B-02 cell 
line (144 nM and 45 nM respectively) (p<0.001, Figure 16). 
 
Next; I assessed in vitro target modulation by looking at phosphorylation 
signal of downstream target in the PI3K/mTOR signaling pathway (i.e. P-AKT 
and S6). Interestingly, while the phosphorylation signal was efficiently inhibited in 
both models upon short drug exposure (i.e. 30 and 90 min); longer drug 
exposure was associated with up regulation of AKT phosphorylation in the RP-B-
01 but not the RP-B-02 model which coincided therapeutic resistance (Figure 17) 
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Figure 16: Differential response of PIK3CA mutated RP-B-01 and RP-
B-02 to LY3023414 in vitro.  A. In growth factor enriched media, 
response to LY3023414 is similar. B. In DMEM media, RP-B-01 cells 
are significantly resistant to LY3023414 compared to RP-B-02. Mean ± 
SD, n =3, representative results from at least triplicate experiments.  
One way ANOVA, Tukey's multiple comparisons test, ***P<0.001. A 










Figure 17: Resistance to LY3023414 in RP-B-01 is associated 
with feedback activation of AKT signaling in vitro.  Prolonged drug 
exposure (24H and 48H) is associated with feedback activation of 
AKT signaling in RP-B-01 cells.   PI3K signaling inhibited at all 
treatment time points in RP-B-02 cells treated with LY3023414. 
Drug concentration for all time points=120 nM. A previous version 
of this figure was published in (Wei, Chintala et al. 2016). 
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C.6. Validation of differential drug response in a 3D culture system of PDX 
derived cell lines  
Drug screening is a key component for drug development and optimizing 
anti-tumor therapies. Traditionally, in vitro drug testing has been conducted in 
monolayer systems that are not capable of recapitulating the tumor complexity.  
Recently, the field has witnessed the rise of interest in 3D culture systems which 
are capable of reproducing tumor complexity while circumventing the cost 
associated with in vivo drug testing (Choi, Lin et al. 2014, Kenny, Lal-Nag et al. 
2015, Elbanna, Chintala et al. 2017). In order to validate our therapeutic 
response data in a more complex system that we can later use for screening of 
further additional compounds or combinations, I was able to develop a novel 
matrigel based 3D culture system consisting of bladder cancer patient derived 
cell lines(Elbanna, Chintala et al. 2017). Using fluorescently labeled cells (GFP or 
RFP), I was able to monitor the growth dynamics of RP-B-01/02 derived 3D 
spheroids under different matrix conditions over nine days in high throughput 
fashion via Thermo ArrayScan XTI (Figure 18). 
 
Interestingly at higher matrigel concentration (10%) and higher cell 
seeding density (16,000 cell/well), we did not observe significant growth in 
sphere size when comparing day 4 (solid bar, Figure 19B) to Day 8 (shaded bar, 
Figure 19B). However this was not the case at lower cell seeding density (2000-
8000 cell/well) irrespective of matrigel concentration (Figure 19). Nevertheless, at 
lower cell density, no significant increase in sphere size was observed overtime. 
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Taking into account that RP-B-02 cells grow more favorably in 3D culture (Figure 
13) in comparison to RP-B-01 cells, I selected 4000 cell/well as an optimal 
seeding condition for both cell lines that would allow for adequate growth 






Figure 18: Development of 3D culture system of PDX- derived 
cell lines for in vitro drug testing.  Representative image of 
Thermo ArrayScan XTI platform used to monitor growth of 




















Figure 19: Growth dynamics of different seeding densities of RP-B-01 
cells in different Matrigel concentrations. A. RP-B-01 cells seeded at 
different densities in media supplemented with 3% Matrigel. Solid bar 
represents GFP fluorescence intensity on DAY4 as detected by Thermo 
ArrayScan XTI. Shaded bar represents GFP fluorescence intensity on 
DAY8. B. RP-B-01 cells seeded at different densities in media 
supplemented with 10% Matrigel.   
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Therapeutic response to PI3K pathway targeted agents (i.e. LY 
LY3023414) was assessed in the same way, using fluorescence as an endpoint 
(Figure 20).  RP-B-02 derived 3D spheroids were more sensitive to PI3K 
pathway inhibitors as compared to RP-B-01. This drug response profile was 
reminiscent of what we observed in vivo using patient derived xenograft models 
derived from the same tumors as well as in vitro in 2D monolayer. Ultimately, the 
goal of this approach is to improve the accuracy with which promising therapeutic 















  Figure 20: Drug response in 3D culture. A. RP-B-01 and RP-B02 
cells were plated into 3D cultures, and cell growth in these spheroids 
was measured via fluorescence intensity on days 4, 8, and 12 after 
plating. 3D cultures were treated with increasing concentrations of 
LY414 following measurements on days 4 and 8. Fluorescence 
intensity data within each experiment were normalized to D12 CTR 
DMSO, and D12 readings were compared. Testing response to 
LY3023414 (dual PI3K/mTOR inhibitor) in 3D shows RP-B-02 derived 
spherorganoids to be significantly more sensitive to LY414 compared 
to RP-B-01; similar to the response observed in vivo. B. A 
representative image of ArrayScan based high throughput drug 
testing done in 96 well plates using fluorescence as readout for drug 
response. Mean ± SD, n =3, representative results from at least 
triplicate experiments.  Student’s t test *p<0.05, ***p<0.01.  
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D. Discussion  
Cisplatin based conventional chemotherapy continues to be the mainstay 
of treatment for patients with MIBC. Nonetheless, recent efforts aiming at better 
molecular characterization of this disease set the stage for a more targeted 
approach to treatment that could provide patients with better outcomes and less 
toxicity(Kamat, Hahn et al. 2016). The challenge however lies in the ability of 
genomic profiling in accurately predicting valid therapeutic targets. In the light of 
this challenge, PDX models provide an invaluable tool for preclinical drug 
development (Jäger, Xue et al. 2015, Lai, Wei et al. 2017). 
 
In our genomic profiling study, the PDXs models maintained the same 
genetic make-up as the original tumors; where 80-90% of all somatic mutations 
were present in both the primary and PDX tumors. However, a small percentage 
(7% and 15% in RP-B-01 and RP-B-02, respectively) of mutations were PDX-
specific and a smaller percentage of mutations (2% and 3% in RP-B-01 and RP-
B-02, respectively) were specific to original patient tumor . These minor 
differences may reflect the changes that happen during tumor progression from 
primary to PDXs  as well as the changes that are charactersitic of innate tumor 
heterogeneity. Overall, our results confirm the high similarity between original 




Due to the importance of cisplatin in management of MIBC, cisplatin 
resistance has been a major challenge in the field. Cisplatin resistance has been 
thought to be either intrisnic or acquired (Galluzzi, Senovilla et al. 2012, Dasari 
and Tchounwou 2014). Several mechanisms have been proposed as mediators 
of cisplatin resistance, including reduction of intracellular drug accumulation 
either by decreased uptake or increase efflux(Galluzzi, Senovilla et al. 2012), 
upregulation of DNA damage repair (Martin, Hamilton et al. 2008) as well as 
lysosomal sequestration(Zhitomirsky and Assaraf 2016). Importantly, RP-B-01, 
which was shown to be cisplatin resistant both in vivo and in vitro, did harbor 
significant   genomic alterations in an array of well known cisplatin resistance 
associated genes, such as Casp8, SLC7A11, TLE4, and IL1A. This shows that 
our genomic profiling was indeed predictive of cisplatin resistance in RP-B-01 
PDX  model. 
 
On the other hand, whole exome sequencing of our MIBC PDX models, 
predicted two canonical  PIK3CA HD mutations (E5452K and E545K in RP-B-01 
and RP-B-02 respectively). However, when I tested therapeutic response to PI3K 
targeted therapy both in vivo and in vitro; I found RP-B-01 to be resistant while 
RP-B-02 is sensitive. Additionaly, targeting of the PI3K/mTOR pathway did not 
result in sustained target modeulation in RP-B-01 (PIK3CA E542K mutant model) 
implying that existence of an alteration in the PI3K/mTOR pathway is not 
predictive of response to PI3K targeted therapy per se. Based on this finding, we 
set out to examine the role of distinct mutation in being predictive of differential 
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response to PI3K targeted therapy. Our hypothesis is partly supported by a 
retrospective study of wide range of solid tumors that have been treated with 
PI3K targeted therapy that has shown that PIK3CA E542K mutant tummors; but 
neither H1047R nor E545K mutant tumors have a trend towards worse 
progression free survival(Janku, Tsimberidou et al. 2011, Janku, Wheler et al. 
2013). Interestingly, when I switched in vitro treatment with LY3023414 in growth 
factor (insulin and EGF) enriched media, the differential response we observed in 
vivo as well as with DMEM media was overcome. Also, when I treated with 
MK2206, an AKT inhibitor the  re-induction of AKT phosphorylation we observed 
with dual PI3K/mTOR inhibitor LY3023414 upon therapeutic resistance in RP-B-
01 was not observed. Collectively, these observations point to alternative 
feedback signaling that is active in RP-B-01 but not RP-B-02. Whether altrenative 
signaling  is driven soley by distinct PIK3CA mutations or also by different 
subtypes (i.e. basal-like VS luminal-like) remains to be better understood. 
 
Taken together, our comprehensive genomic profiling of two MIBC PDX 
models is predictive of response to cisplatin but not PI3K tageted therapy(Wei, 
Chintala et al. 2016). Distinct PI3KCA muations in addition to distinct molecular 
subtypes in our models are two key points that require further investigation in 
order to derive a better predictive algorithm for response to targeted therapy in 
patients with MIBC. Ultimately our goal is to guide the clinical implementation of 
targeted therapy in the management of bladder cancer. 
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CHAPTER IV: PIK3CA E542K MUTATION IN BLADDER CANCER CONFERS 
RESISTANCE TO PI3K TARGETED THERAPY 
A. Chapter Summary 
The current goal of precision medicine is to develop more tailored 
treatments for cancer patients in order to improve prognosis and limit toxic side 
effects. However the challenge is to identify molecular aberrations that are 
predictive of response. Genomic profiling of two MIBC PDX models developed in 
our lab (Wei, Chintala et al. 2016) (RP-B-01 and RP-B-02) identified two distinct 
PIK3CA HD mutations in each model (E542K and E545K respectively). 
Additionally they were found to be of distinct molecular subtypes (basal-like and 
luminal-like respectively). Despite the existence of PIK3CA mutations in both 
models, I found them to respond differently to PI3K targeted therapy both in vivo 
and in vitro; where RP-B-01 was resistant while RP-B-02 was sensitive. Based 
on this finding, I set out to compare the role of distinct PIK3CA HD mutations in 
driving differential response to treatment by transfecting isogeneic HEK cells with 
the mutations of interest. Interestingly, PIK3CA E542K mutation conferred a 
significant growth advantage to HEK cells specifically in 3D culture. HEK cells 
transfected with E542K but neither WT nor E545K mutant PIK3CA were 
significantly resistant to dual PI3K/mTOR inhibitor LY3023414 both in 2D and 3D 
culture. Similar to what we observed in RP-B-01, resistance observed in PI3KCA 
E542K transduced HEK cells was associated with lack of efficient target 
modulation in comparison to PI3KCA E545K transduced HEK cells where AKT 
phosphorylation was adequately inhibited at all treatment time points. Next, to 
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showing the role of distinct PIK3CA mutations in driving differential treatment 
response; I examined potential alternative signaling that can drive feedback 
resistance. Interestingly, I found ERK phosphorylation to be induced upon 
resistance to PI3K inhibition in RP-B-01 and associated with MYC stabilization. 
Additionally, I found combining LY3023414 treatment with JQ1; a bromodomain 
inhibitor that is known to inhibit MYC and its downstream targets(Mertz, Conery 
et al. 2011) to be significantly synergistic in RP-B-01 but not RP-B-02. Synergy 
found with JQ1 was specific to LY3023414 but not helpful with resistance 
induced upon cisplatin treatment in RP-B-01. Taken together, this chapter reports 
a novel predictive role for distinct PI3KCA HD mutations in driving response to 
PI3K targeted inhibition. It also provides a mechanistic rationale for drug 
combinations that can potentially override resistance to PI3K targeted therapy 
and improve its clinical outcomes. 
 
B. Background and Rationale 
The field of bladder cancer management is lagging behind in comparison 
to other solid tumors were targeted therapy is currently the standard of care. In 
this disease, cisplatin; which is a conventional chemotherapeutic agent continues 
to be the mainstay of therapy (Leow, Martin-Doyle et al. 2014, Kamat, Hahn et al. 
2016). The lack of predictive molecular stratification has impeded the success of 
targeted therapy (Shah, McConkey et al. 2011).  
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A recent attempt at comprehensive molecular characterization of bladder 
cancer has identified PI3K/mTOR pathway as one of the most frequently 
deregulated signaling pathways in this disease where PI3K signaling is 
deregulated in 42%of bladder cancer cases, 25 % of these cases are due to 
PIK3CA activating mutations (Platt, Hurst et al. 2009, Network 2014). PIK3CA 
activating mutations are single amino acid substitutions that occur either in the 
helical (E545K, E542K) or kinase domain (H1047R). Functional studies have 
shown different mechanisms of activation by helical and kinase domain 
mutations, where H1047R is dependent on P85 binding but not on RAS binding, 
however the opposite holds true for helical domain mutations which are so far 
thought to be functionally similar (Miled, Yan et al. 2007, Zhao and Vogt 2008). 
 
Preclinical data and data from phase I and II clinical trials suggest that 
PIK3CA mutation status can predict response to PI3K targeted therapy (Janku, 
Tsimberidou et al. 2011). A recent retrospective non randomized study that 
analyzed data from patients with wide range of solid tumors who were treated 
with PI3K targeted therapy concluded that patients with wide range of solid 
tumors who were treated with PI3K targeted therapy who harbored a PIK3CA 
H1047R mutation had a higher partial response (PR) rate (38% vs. 10%; 
p=0.018) and a trend towards having a longer median progression free survival 
(PFS) (5.7 months vs. 2 months; p=0.06) compared to patients with helical 
domain PIK3CA mutations treated on the same protocols. The fact that PIK3CA 
H1047R mutation is predictive of response compared to helical domain mutations 
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was attributed to the coexistence KRAS mutations with helical but not kinase 
domain mutations (Janku, Wheler et al. 2013). 
 
However; unlike most solid tumors, bladder cancer holds a unique position 
where PIK3CA helical domain mutations are more common compared to kinase 
domain mutations; accounting for 80% of cases driven by PIK3CA activating 
mutations (Network 2014). The selective pressure for helical domain mutations in 
bladder is not yet understood (Knowles, Platt et al. 2009, Knowles and Hurst 
2015); however it might indicate that PIK3CA mutations have different roles in 
different histological backgrounds and therefore a different capacity of predicting 
response to therapy. A similar phenomenon has been reported for BRAF 
mutations; where a BRAF V600E mutation is predictive for response to BRAF 
inhibitors in melanoma, but not in colorectal cancer (Janku, Wheler et al. 2013). It 
is therefore important to interpret data from retrospective clinical studies 
cautiously and take into account the distinctive biology of each tumor as well as 
the inherent weakness of retrospective as opposed to randomized controlled 
prospective trials. 
 
Nonetheless; it is important to note that in bladder cancer PIK3CA helical 
domain mutations are not exclusively coexistent with RAS mutations; therefore 
RAS activation cannot always explain resistance to therapy. In some instances, 
double mutations were identified in PIK3CA; one case with a HD and a KD 
domain mutation, and one case with two mutations in the HD domain (E542K 
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E545K); indicating an additive non redundant effect of multiple PIK3CA mutations 
in this disease (Sjödahl, Lauss et al. 2011); and therefore potentially a differential 
therapeutic potential. 
 
Although the rate of PIK3CA activating HD activating mutations in bladder 
cancer is high; mTOR inhibitors were exclusively used in bladder cancer trials 
despite the absence of mTOR mutations in this disease(Houédé and Pourquier 
2015). Only two bladder cancer trials are utilizing novel PI3K inhibitors (Munster, 
Aggarwal et al. 2015), (NCT01551030). Therefore, the significance of PIK3CA 
HD mutations in terms of predicting therapeutic response is yet to be determined. 
 
We have previously reported that two MIBC PDX models (RP-B-01 and 
RP-B-02) that carry distinct PIK3CA helical domain (HD) mutations (E542K and 
E545K respectively) respond differently to dual PI3K/mTOR inhibitor 
(LY3023414), where one model is sensitive (RP-B-02, PIK3CA E545K MUT) 
while the other is resistant (PIK3CA, E542K MUT) (Figures 9,10) (Wei, Chintala 
et al. 2016). Additionally, our comprehensive genomic analysis showed that each 
model is of distinct subtype; where RP-B-01 is basal like while RP-B-02 is luminal 
like.  
 
In this chapter, I explore the role of distinct PI3KCA HD mutations in 
driving differential response to PI3K targeted therapy by transfecting isogeneic 
cells (HEK cells) with either WT or mutant PIK3CA. Using transfected HEK cells, 
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I examine the oncogenic potential of each mutation and its role in driving 
differential response to treatment. We also performed a comprehensive gene set 
enrichment analyses (GSEA) on gene expression data from our PDX models and 
publicly available data from The Cancer Genome Atlas (TCGA) in order to 
identify distinct signaling mechanisms downstream of those two mutations that 
can play a role in therapeutic resistance. Subsequently, I tested rational drug 
combinations capable of overriding resistance to PI3K targeted therapy (i.e. 
bromodomain inhibitor). Taken together, this chapter is focused on dissecting 
molecular mechanisms of resistance to PI3K targeted therapy in PIK3CA E542K 
mutant bladder cancer and providing a rationale for novel drug combinations that 
can override resistance to therapy.   
 
C. Results 
C.1. PIK3CA HD mutations drive distinct signaling irrespective of tumor subtype 
The differential therapeutic response that I observed in our bladder PDX 
models (Wei, Chintala et al. 2016), could be mutation dependent, subtype related 
or a combination of both. To determine, the mutation-specific signaling pathways 
that could play a role in therapeutic resistance irrespective of tumor subtype, we 
performed a comprehensive gene set enrichment analyses (GSEA) on gene 
expression data from our PDX models and publicly available data from The 
Cancer Genome Atlas (TCGA). We separated the gene expression data sets into 
different categories based on the PIK3CA mutation status and the molecular 
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subtype to identify pathways that were consistently enriched in cells with E542K 
mutation versus cells with E545K mutation in a subtype independent fashion. 
 
Interestingly, this analysis identified differential metabolic pathways 
between E542K and E545K mutant tumors. E542K mutant tumors are highly 
enriched with alternative pathways that are often utilized in hypoxic conditions 
(Figure 21) while E545K mutant tumors have enrichment for oxygen dependent 


































Figure 21: PIK3CA E542K MUT dependent pathways. Heatmap 
comparing E542K and E545K mutated samples using RNA-
sequencing data from the TCGA Bladder Cancer (BLCA) data set and 
from RNA-sequencing of RP-B-01 and RP-B-02 cells. Each column 
represents a different comparison of samples with E542K mutations 
and E545K mutations. The heatmap values represent GSEA 
enrichment scores (ES) utilizing the C2: curated gene sets database 
with positive values (yellow/orange) representing enrichment in the 
E542K condition and negative values (black/blue) representing 
enrichment in the E545K condition. The callout box outlined in red 
highlights the C2 gene sets that are enriched for E542K samples in all 























Figure 22: PIK3CA E545K MUT dependent pathways. Heatmap 
comparing E542K and E545K mutated samples using RNA-sequencing 
data from the TCGA Bladder Cancer (BLCA) data set and from RNA-
sequencing of RP-B-01 and RP-B-02 cells. Each column represents a 
different comparison of samples with E542K mutations and E545K 
mutations. The heatmap values represent GSEA enrichment scores (ES) 
utilizing the C2: curated gene sets database with positive values 
(yellow/orange) representing enrichment in the E542K condition and 
negative values (black/blue) representing enrichment in the E545K 
condition. The callout box outlined in red highlights the C2 gene sets that 
are enriched for E545K samples, the listed gene sets to the right show 
enrichment for at least 4 out of the 5 comparisons.   
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C.2. E542K mutational status is associated with distinct metabolic behavior in 
urothelial cells 
Altered metabolism in urothelial cells has been  implicated in bladder 
cancer development where cancer progression is linked to glycolytic switch 
(anaerobic  breakdown of glucose) and increased expression of genes related to 
the pentose phosphate pathway (glucose-6-phosphate dehydrogenase [G6PD]) 
and fatty-acid synthesis (fatty acid synthase [FASN]). Interestingly PI3K/mTOR 
signaling is known to be central to this switch (Massari, Ciccarese et al. 2016, 
von Rundstedt, Rajapakshe et al. 2016). Nonetheless, our analysis shown in 
figures 21 and 22 supports the idea that this switch is more likely favored by an 
E542K mutation rather than an E545K mutation. 
 
It is not ideal to test this observation in urothelial cancer cells 
conventionally cultured in monolayer because of the uniform exposure of cells to 
non-physiologic oxygen tension. However, the 3D culture model that I have 
developed (Figures 13, 18-20) would provide a very attractive tool in this setting 
where cancer cells can spontaneously generate a multi-cellular 3D structure.  
This culture system can more faithfully mimic the tumor complexity in comparison 
to cells cultured in monorlayer since it allows for testing oxygen tension which is 
a surrogate marker for distinct tumor microenvironment that influences drug 
response(Park, Jeong et al. 2016). In order to test this hypothesis more 
thoroughly, I wanted to include more PIK3CA mutant bladder cancer cell lines to 
my panel in addition to RP-B-01 and RP-B-02 PDX derived cell lines. 
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Recently, a panel of 40 bladder cancer cell lines have been characterized 
with respect to subtype as well as recurring mutations in bladder cancer (i.e. 
PIK3CA, FGFR, RAS mutations) (Earl, Rico et al. 2015). This invaluable 
resource included 8 bladder cancer cell lines that harbor PIK3CA HD mutations. 
Of those eight cell lines, I was able to get hold of two additional cell lines to add 
to my panel: TCC-SUP which is basal-like and carries PIK3CA E545K mutation 
in addition to 253J which is basal-like and carries PIK3CA E545G mutation 
(Figure 23A). 
 
First, I tested response to LY3023414 in those additional cell lines in 
comparison to my original PDX derived cell lines. Importantly, I found TCC-SUP 
to be significantly sensitive to LY3023414 and to behave like RP-B-02 in 
comparison to RP-B-01 and 253J which were less sensitive. This strengthens the 
idea that PIK3CA E545K (TCC-SUP, RP-B-02) mutation is inherently more 
sensitive to treatment compared to E542K mutation. It would be interesting to 
see whether E545G mutation (253J) clusters with E542K (RP-B-01) mutation, 
hence the similar therapeutic response. However, the lack of patient samples 
that carry this rare mutation in TCGA data hinders against investigating this 







Figure 23: PIK3CA E545K MUT cell lines are more sensitive to PI3K 
targeted inhibition. A. Table highlighting the subtype and PIK3CA 
mutation status of bladder cancer cell lines used in the experiment. B. 
PIK3CA E545K mutant TCCSUP and RP-B-02 are both sensitive to 
LY3023414 single agent compared to basal-like RP-B-01 (E542K MUT ) 
and 253J (E545G MUT). Fold change refers to degree of inhibition in 
comparison to vehicle (DMSO) control. Mean ± SD, n =3, representative 
results from at least triplicate experiments.  One way ANOVA, Tukey’s 
multiple comparisons test, *P= 0.01, **P<0.01, **P<0.001.   
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Next, I plated equal number of cells from all four cell lines (Figure 23A), 
and allowed them to form 3D structures per optimized conditions for 3D culture 
formation and growth (Figures 18-20). On Day 12, I incubated well established 
bladder cancer spheres with a spheroid permeable hypoxia probe, LOX-1 
(Zhang, Hosaka et al. 2010, Park, Jeong et al. 2016) for 24 hours. On the next 
day, LOX-1 red fluorescence was measured by H1 Synergy microplate 
reader(Sada, Nishikawa et al. 2016). Absorption and phosphorescence peaked 
at 483 nm and 616 nm respectively (Zhang, Hosaka et al. 2010). Interestingly, I 
found the fluorescence intensity to be significantly higher in RP-B-01 (E542K 
MUT) compared to both RP-B-02 and TCC-SUP (E545K MUT), while both 








Figure 24: Uptake of LOX-1 hypoxia probe in bladder cancer 
spheroids.  Each type of spheroid was incubated with 3D permeable 
hypoxia probe, LOX-1, for 24 hours on Day 12 of 3D formation. The 
mean fluorescence intensity was measured by h1 Synergy 
microplate reader. Each dot represents one well. Mean ± SD, n =3, 
representative results from at least triplicate experiments.  One way 




For a more accurate evaluation of the distribution and uptake of LOX-1 
hypoxia probe in bladder cancer spheroids, I further evaluated the hypoxic 
regions within spheroids by confocal microscopy in order to take into account the 
different shape/size of spheres (Figure 13). In order to reach that goal, I co-
stained the spheres with blue nuclear stain Hoechst to uniformly stain all nuclei in 
the sphere 30 min prior to imaging which was done 24 hours after incubation with 
LOX-1. 
 
Interestingly, I found the uptake of LOX-1 red signal indicative of hypoxia 
to show a higher trend in RP-B-01 spheres compared to RP-B-02 spheres. The 
fluorescence was normalized to the nuclei within the sphere as indicated by 
positive Hoechst stain (Figures 25, 26). The RP-B-02 spheres has seemingly 
less hypoxic regions despite the compactness of the RP-B-02 spheres in 
comparison to RP-B-01 spheres (Figure 13) which is thought to be a key player 
in driving hypoxia in the core of the sphere (Park, Jeong et al. 2016). Using q-
PCR I tested the expression of fatty acid synthase (FASN), one the genes that is 
induced upon the glycolytic switch in bladder cancer (Massari, Ciccarese et al. 
2016, von Rundstedt, Rajapakshe et al. 2016) and is associated with progression 
and therapeutic resistance in bladder cancer(Jiang, Li et al. 2012, Zheng, Gao et 
al. 2016). FASN significantly overexpressed in RP-B-01 compared to RP-B-02 
and was induced in a time dependent manner upon prolonged exposure of RP-B-
01 cells to LY3023414 which coincides with resistance.   
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Figure 25: Confocal based evaluation of the hypoxic status of 
PDX derived spheroids. Imaris ™ based reconstruction and 
segmentation of PDX derived spheroids  for visualization of the 
distribution of Red (LOX-1) and blue (Hoechst) signals. The 
images are representative of at least 5 replicates of each condition 

















Figure 26: Quantification of the  LOX-1 fluorescence intensity 
in PDX derived spheroids. LOX-1 uptake was quantified as 
ratio between red signal (LOX-1) and blue signal (Hoechst). 
This ratio allows for accounting for sphere variability in shape 
and size which was accounted for using Hoechst which stains 
all nuclei. B0-1 trended towards higher uptake of LOX-1 in 
comparison to RP-B-02. However the results were not 











Figure 27: FASN is overexpressed in RP-B-01 and induced upon 
resistance to LY3023414. A: qPCR confirms significantly more 
FASN in RP-B-01 compared to RP-B-02 similar to the RNA-Seq 
analysis. B. FASN is downregulated at 90 min treatment (TTT) of 
RP-B-01 cells with LY3023414, a time point where P-AKT is 
efficiently inhibited by the drug. However, it is induced upon 
prolonged drug exposure (48 hours) which coincided with 
upregulation of P-AKT and resistance to LY3023414.  
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C.3. E542K mutant PI3K protein confers significant growth advantage to HEK 
cells 
In order to validate the distinct growth and metabolic behavior of the two 
PIK3C HD mutations (PIK3CA E542K & E545K); I transfected isogeneic 
HEK293T cells with either WT or MUT PIK3CA plasmids.  Although HEK cells do 
not represent an ideal biologically relevant background, they are readily 
transfectable cells that express WT PI3K protein and that have been previously 
used to test the behavior of different PI3K isoforms(Nakanishi, Walter et al. 
2016). 
 
Using western blotting, I confirmed the expression of protein of interest 
(WT or Mutant) in transfected cells by probing for HA-tag expression. 
Overexpression of PI3K protein was associated with upregulation of P-AKT in 
comparison to non-transfected control (empty vector); which shows that the 
overexpressed protein is functional and thus mechanistically testable (Figure 28). 
Next, using Alamar blue proliferation based assay, I monitored the growth of HEK 
cells expressing WT and mutant PI3K protein over time both in monolayer and in 
3D culture. Both forms of mutant PI3K protein conferred a growth advantage to 
HEK cells compared to WT protein in monolayer (~20% on days 2 and 3) (Figure 
29A). Interestingly however; in 3D culture, I found that E542K mutant protein 
conferred a significant growth advantage to HEK cells (~50-100%) in comparison 


























Figure 28: Development of isogenic HEK cells that are either WT 
or carry the PIK3CA HD mutation (E542K; E545K). 
Overexpression of PI3K protein was associated with upregulation 
of P-AKT in comparison to non-transfected control (NT); which 
shows that the overexpressed protein is functional and thus 



















Figure 29: PIK3CA E542K mutation confers significant growth 
advantage to HEK cells. A. Growth of HEK cells (WT/MUT) 
monitored in monolayer overtime using Alamar blue fluorescence 
proliferation-based assay. Mutant protein conferred growth 
advantage to cells (average of 3 replicates). B. In 3D Matrigel- 
based system, HEK PIK3CA E542K MUT cells grew significantly 
faster than E545K mutants. Mean ± SD, n =3, representative results 
from at least triplicate experiments.  One way ANOVA, Tukey's 
multiple comparisons test, ***P<0.001. 
107 
Next, using q-PCR, I tested the expression of FASN in transfected HEK 
cells to examine whether over expression of distinct PIK3CA mutations would 
influence gene expression and mirror the overexpression of FASN in RP-B-01 
cells. Interestingly, in PIK3CA E545K transfected HEKs , I found FASN, one of 
the markers of altered metabolism in urothelial cancer to be significantly 
downregulated in comparison to E542K mutant and WT cells (Figure 30).This 
finding mirrors the differential metabolic behavior that I observed in bladder 
















Figure 30:  FASN is reduced in PIK3CA E545K MUT cells. q-PCR 
show significant downregulation of FASN in E545K MUT cells 
compared to E542K MUT cells. Mean ± SD, n =3, representative 
results from at least triplicate experiments.  One way ANOVA, 
Tukey's multiple comparisons test, **P<0.01. 
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In 3D culture, I assessed the distribution and fluorescence intensity of 
Mitotracker signal in PIK3CA transfected HEK cells as an alternative tool for 
assessing the metabolic changes associated with HD PIK3CA 
mutations(Fijalkowska, Xu et al. 2010) . Similar to what I observed with the 
hypoxia probe LOX-1 (Figures 24-26), I found a distinct uptake and distribution of 
the Mitotracker in E542K and E545K mutant HEK spheroids (Figure 31). 
Interestingly,   I found the Mitotracker fluorescence signal to be significantly less 
in both E542K and E545K mutant HEK spheroids compared to their WT 
counterpart after being normalized to the Hoechst blue signal to account for the 
striking difference in spheroid sizes (Figure 32). However, there was no 
significant difference between E542K and E545K mutant spheroids (Figure 32). 
Therefore, for further validation my goal is complement this experiment with LOX-
1 staining to overcome the limitations associated with Mitotracker as a tool for 












Figure 31: Uptake and distribution of Mitotracker Red in PIK3CA 
MUT HEK spheroids.  projected image of multi-slice confocal 
imaging of PIK3CA mutant s spheres show distinct uptake and 
distribution of Mitotracker Red signal in E542K MUT in 
comparison to E545K MUT spheres. The images are 
representative of at least 5 replicates of each condition done in 3 








Figure 32: PIK3CA mutation status influence Mitotracker signal 
intensity in HEK spheroids. Confocal imaging-based quantitative 
analysis of the Red (Mitotracker)/Blue (Hoechst) signal in images slices 
taken per spheroid per condition show that over expression of WT 
PIK3CA in HEK cells is associated with significantly higher mitotracker 
signal in comparison to both non transfected (NT) and mutant (MUT) 
conditions. No significant difference in the intensity of the red signal was 
detected in MUT HEK spheroids. . Mean ± SD, n =6, representative 
results from at least triplicate experiments.  One way ANOVA, Tukey's 
multiple comparisons test, **P<0.01. 
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C.4. PIK3CA E542K mutation is associated with weaker binding of LY3023414 
Thus far, I have shown that PIK3CA HD mutations drive distinct mutation 
dependent signaling in bladder cancer that is reflected in the behavior of PDX 
derived spheroids as well as in PIK3CA mutant HEK cells/spheroids. These 
findings provide a solid foundation for testing whether differential response to 
PI3K targeted inhibition is mutation dependent.  
  
First, I sought out collaboration with the department of biotechnology, VIT 
University, Vellore, India in order to investigate whether the mutation type could 
influence the affinity of the compound (LY3023414) to the substrate (PI3K 
protein) in a distinct manner. In silico analysis of the binding affinity of 
LY3023414 to WT and mutant PI3K protein started with computationally deriving 
the crystal structure of Phosphoinositide-3-kinase (PI3K) alpha lipid kinase. 
Using NCBI BLASTp homology search(Johnson, Zaretskaya et al. 2008) the 
crystal structure of Phosphoinositide-3-kinase (PI3K) alpha lipid kinase (PDB ID: 
4YKN with 2.9 Å resolution) was built with 99% sequence identity and 99% query 
coverage against the target mutant sequences (E542K and E545K respectively) 
and it was used as a template for the homology modeling. The structural quality 
of the model produced by MODELLER(Fiser and Šali 2003) was verified by the 
Ramachandran plot, which reveals that phi/psi angles of the residues are located 
in favored regions (97.7% and 97.9% respectively). 3D verification revealed that 
the compatibility of the residues are 80.73% and 81.59% respectively and the 
structures have the average score of >0.2, which indicates the excellent 
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compatibility among the residues. The ERRAT confirmed non-bonded contacts 
between the diverse atoms. The quality factor of the modeled mutants was found 
to be 85.12 and 83.64 respectively. The ProSA module projected the Z-score of -
9.22 and -9.89 for RP-B-01 and RP-B-02 respectively. The complete analysis of 
the results supported the great quality of the modelled protein. 
 
Using the predicted in silico model for both forms of mutant PI3K protein 
(E542K and E545K mutant); molecular docking for both mutations (found in RP-
B-01 and RP-B-02 respectively) with the PI3K/mTOR pathway inhibitor 
LY3023414(Fiser and Šali 2003) was done. The docking in the context of the 
E545K mutation resulted in higher binding energy compared to the E542K 
mutation with the C-score of 4.23 and 2.21 respectively. Moreover, H-bond 
interaction with Glu237 (distance 3.2 Å) and Lys678 (distance 3.3 Å) was 
detected in the context of the E545K mutation while found 2 H-bond formation 
with Cys838 (distance 3.4 Å) and Ser312 (distance 3.2 Å) were detected with the 
E542K mutant. Overall, E545K mutation was found to be associated with 
improved interaction of LY3023414 with PI3K protein (Figure 33). On the other 
hand; E542K mutation was associated with poor binding of LY3023414 to the 





Figure 33: Docking results of PI3K E542K MUT and 
LY3023414.  A. Binding mode of LY3023414 with PI3K 
E542K MUT. B. PI3K E542K MUT residues involved in H-
bond formation with LY3023414. 
Figure 34: Docking results of PI3K E545K MUT and 
LY3023414. A. Binding mode of LY3023414 with E545K 





To figure out the stability of the complexes PI3K (E542K-LY3023414) and 
PI3K (E545K-LY3023414), molecular dynamic simulation (MDS) was 
implemented and the generated graphs were analyzed(Turner 2005, Hess, 
Kutzner et al. 2008). The first thing tested in the MDS study was Root-mean-
square deviation of atomic positions (RMSD). The displacement of heavy atoms 
after 45000 ps of MD simulation was determined by g_rms of GROMACS 
package. The RMSD of the complexes PI3K (E542K)-LY3023414 and PI3K 
(E545K) - LY3023414 are shown in (Figure 35).  As illustrated in the figure, the 
PI3K (E545K) - LY3023414 complex has sudden rise in the beginning and after 
5000 ps RMSD value stabilized at 0.65 nm. Whereas, the PI3K (E542K)-
LY3023414 complex has gradual increase in the RMSD value from 0.42 nm to 
0.62 nm till 35000 ps. Later the value gets stabilized after 35000 ps at 0.68 nm. 
The complete analysis of RMSDs of the complexes PI3K (E542K)-LY3023414 
and PI3K (E545K) - LY3023414 reveals that the PI3K (E545K) - LY3023414 















Next, root mean square fluctuation (RMSF) was measured to predict the 
average movement of the atoms on binding of LY3023414 with PI3K protein that 
carries either the E542K or E545K mutation after 45000 ps using the g_rmsf. The 
PI3K (E542K)-LY3023414 complex was found to have fluctuations ranging from 
0.08 nm to 1.05 nm (Figure 36A). The LY3023414 binding site residues Cys838 
and Ser312 in the context of the E542K mutant PI3K protein have 0.09 nm and 
0.22 nm variation. Similarly, the LY3023414 binding site residues of E545K 
mutant PI3K protein, Cys678 and Glu237 have the fluctuation of 0.07 nm to 0.21 
nm. As depicted in (Figure 36B), the Lys545 of RP-B-02 model has the variation 
of 0.12 nm and the residue Lys542 in the RP-B-01 treatment resistant model has 
the fluctuation of 0.16 nm. The complete observation of the fluctuation ranges 
Figure 35: RMSD Plot. Backbone RMSD plots of PI3K E545K 
MUT -LY3023414 complex (black) and PI3K E542K MUT-
LY3023414 complex (red). 
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reveals that the E545K mutation influences some structural changes in PI3K 
protein and cause increased binding affinity of LY3023414 towards PI3K and 






























Figure 36: RMSF Plot. A. RMSF plot for backbone atom of 
PI3K E545K MUT -LY3023414 complex (black) and PI3K 
E542K MUT -LY3023414 complex (red) showing distinct 
fluctuations of atoms in both conditions.  B. RMSF plot for 
specific Lysine residues at the 542 and 545 positions in E542K 
(red) and E545K mutants (black). 
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To further confirm that distinct missense mutations in the PI3K protein 
helical domain drive distinct conformational changes in the PI3K treatment which 
influence the affinity between the protein and the drug; the radius of gyration 
(Rg); a measure of the compactness of protein, was calculated after 45000 ps. 
The Rg plot of the two different complexes is depicted in (Figure 37). The PI3K 
(E542K)-LY3023414 complex shows minor deviation at the start of the 
simulation. After 25000 ps, the Rg value started rising till 3.25 nm. Then, there is 
sudden decrease in the Rg value which gets stabilized at 3.23 nm. The PI3K 
(E545K) - LY3023414 complex showed rapid increase at the beginning , then the 
Rg value started decreasing gradually then it reached 3.15 nm till 30000 ps. 
Then the Rg value is stable at 3.15 nm after 30000 ps. The difference in the 
stability status of the two complexes indicates that the binding of LY3023414 with 
E545K mutant is influenced by distinct conformational changes in the protein. 
 
Lastly, the H-bond distances of PI3K (E542K)-LY3023414 and PI3K 
(E545K)-LY3023414 complexes (Figure 38); showed that the PI3K (E542K)-
LY3023414 complex had fluctuating H-bond distances of 3 nm till 10000 ps and 
3.2 nm distances from 10000 ps to 27000 ps. After 30000 ps the H-bond 
distance decreases from 3.4 nm to 3.2 nm. Whereas the PI3K (E545K)-
LY3023414 complex had a more stable H-bond distance overall (average of 3.28 
nm).  Taken together, the PI3K (E545K)-LY3023414 complex interaction is 













Figure 37: Rg Plot of Cα atoms. Rg plots of Cα atoms of PI3K 
E545K-LY3023414 complex (black) and PI3K E542K-LY3023414 
complex (red). Radius of gyration (Rg) is a measure of protein 
compactness, the higher the Rg score (red/E542K), the less stable 











Overall preliminary in silico analysis supports the idea that distinct PIK3CA 
mutations drive distinct conformational changes in the protein that influence 
protein-drug binding and stability of the formed complex in a manner that could 
potentially affect therapeutic response. 
 
It is therefore important to test whether this is functionally translated in a 
manner where distinct mutations influence the protein kinase activity. Using ADP-
Glo assay we tested the effect of LY3023414 on the kinase activity of the two 
mutant forms of PI3K protein (E542K and E545K mutants). Interestingly, we did 
Figure 38: H-bond plot. H-bond distances between the 
PI3K E545K-LY3023414 complex (black) and PI3K 
E542K-LY3023414 complex (red). 
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not find a significant difference between the two mutations (Figure 39), implying 
that resistance associated with distinct conformational changes induced by the 
E542K mutation are not driven by direct effect on the protein kinase activity but 






















 Figure 39: LY3023414 does not have differential effects on 
kinase activity of PI3K protein carrying distinct HD PIK3CA 
mutations. A. IC50 of LY3023414 with respect to kinase activity 
of PI3K E542K MUT is 1.65E-08 and 1.29E-08 (duplicates). B. 
IC50 of LY3023414 with respect to kinase activity of PI3K E545K 
MUT is 1.69E-08 and 1.47E-08 (duplicates) 
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C.5. HEK cells harboring the E542K mutant PI3K protein are resistant to 
LY3023414 
Next to investigating the distinct LY30234314-PI3K interactions induced 
by PIK3CA HD mutations in silico, I tested whether response to LY3023414 is 
indeed mutation specific using PIK3CA transfected HEK cells. Cells transfected 
with the E542K mutant protein were significantly more resistant to LY3023414 
when treated in monolayer at all treatment time points compared to E545K 
mutant cells (P<0.001) (Figure 40A).   Similarly, when treated in 3D, E542K 
mutant spheroids were strikingly resistant to treatment compared to their E545K 
mutant counterparts, yet at a lower concentration range (Figure 40B). 
Collectively, these data provide a proof of concept that there is a potential 
independent role of distinct PIK3CA mutations in driving differential response to 





Figure 40:  HEK cells harboring the E542K mutant PI3K protein 
are resistant to dual PI3K/mTOR inhibitor LY3023414. A. Cells 
treated in monolayer with LY3023414 at different concentration 
and time points (72 hour treatment time point shown). HEK E545K 
MUT cells are significantly sensitive to treatment compared to 
other clones. B. Cells treated in matrigel based 3D culture with 
LY3023414 on Days 4 and 8.  HEK E545K MUT cells are 
significantly sensitive to treatment compared to other clones.  
Mean ± SD, n =3, representative results from at least triplicate 
experiments.  One way ANOVA,   Tukey's multiple comparisons 
test, ***P<0.001. 
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C.6. Resistance to LY3023414 in E542K mutant HEK cells is associated with 
inefficient target modulation  
Therapeutic resistance observed in RP-B-01 is associated with 
upregulation of AKT phosphorylation upon extended exposure to LY3023414 in 
vitro (24H and 48H) as well as in vivo. Therefore I tested the effect of LY3023414 
treatment on downstream PI3K/mTOR signaling in PIK3CA transfected HEK 
cells. Interestingly, at 24 and 48H, AKT phosphorylation was inhibited in PIK3CA 
E545K mutant HEK cells but not in PIK3CA E542K mutant cells (Figure 41). 
These data corroborates our findings in the resistant E542K mutant RP-B-01 
model and further strengthens the rationale behind a mechanistic role of distinct 






Figure 41: Resistance to PI3K targeted inhibition in E542K 
mutant HEK cells is associated with inefficient target modulation. 
A. HEK cells transfected with PIK3CA E542K MUT treated with 
LY3023414 at different time points. AKT phosphorylation was not 
inhibited compared to B. PIK3CA E545K transfected cells were 
both AKT phosphorylation and total PI3K protein were decreased 
upon exposure to LY3023414 at different time points tested.      
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C.7. RAS-MAPK signaling is activated in RP-B-01 and associated with 
stabilization of MYC 
The ultimate goal of studying therapeutic resistance is to identify 
alternative signaling pathways that are activated in resistant tumors and that are 
potentially targetable. In addition to the hypoxia driven metabolic pathways that 
we found to be significantly enriched in E542K mutant bladder tumors (Figures 
21,22),  This analysis identified ERK/MAPK/growth factor signaling pathways as 
being significantly activated in E542K mutated cells, including RP-B-01 cells 
(Figure 21) in comparison to their E545K mutant counterparts.  Interestingly, this 
corroborates with previous research that has looked at potential cross talk 
between PI3K/mTOR and MAPK signaling in driving therapeutic resistance (Zhu, 
Blenis et al. 2008, Dey, Leyland-Jones et al. 2015). Indeed when I looked at 
downstream signaling in RP-B-01 cells treated with LY3023414 at different time 
points; I found that feedback activation of AKT phosphorylation that is induced at 
24 and 48 hours of treatment is associated with up-regulation of ERK 
phosphorylation and stabilization of MYC compared to control non treated 
condition (Figure 42). At the gene expression level, I found MYC to be 
significantly upregulated in RP-B-01 compared to RP-B-02 and to be two-fold 
higher in HEK-E542K mutant cells in comparison to their E545K mutant 
counterparts.  Additionally resistance to LY3023414 in RP-B-01 cells trended 





Figure 42: Resistance to LY3023414 in RP-B-01 is associated with 
activation of MAPK signaling and stabilization of MYC. A. AKT and 
ERK phosphorylation were inhibited upon 90 minute treatment of 
RP-B-01 cells with LY3023414. Feedback activation of AKT 
phosphorylation upon extended exposure to LY3023414 (24 and 48 
hour) is associated with feedback ERK phosphorylation and 
stabilization of MYC in comparison to non-treated control condition. 
B. RP-B-02 cells were responsive to LY3023414 are all time points 
tested. AKT and ERK phosphorylation were inhibited at all time 
points tested. MYC levels at 24 and 48 hours were similar to non-





Figure 43: PIK3CA E542K mutation status is associated with 
induction of MYC RNA levels.  A. MYC RNA levels are 
significantly higher in RP-B-01 (E542K MUT) in comparison to 
RP-B-02 (E545K MUT). B. MYC gene expression is induced in a 
time dependent manner upon exposure to LY3023414 which 
coincides with treatment resistance and stabilization at the protein 
level as assessed by WB. C. Overexpression of PIK3CA E542K 
MUT is associated with significant induction of MYC at the RNA 
level in comparison to both WT and E545K MUT conditions. Mean 
± SD, n =3, representative results from at least triplicate 
experiments.  One way ANOVA, Tukey's multiple comparisons 
test, *P<0.05, **P<0.01. 
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C.8. Combined PI3K/mTOR and BET inhibition sensitizes RP-B-01 to 
LY3023414  
The cross talk between PI3K and MAPK signaling which impinges 
downstream on MYC has been previously proposed as a potential mechanism of 
resistance in PIK3CA mutant (Dey, Leyland-Jones et al. 2015) and MYC driven 
metastatic breast cancer (Stratikopoulos, Dendy et al. 2015).  
Bromodomain inhibitors are drugs that target the bromodomains which act 
as readers that bind acetylated lysines in histone tails and thus regulate gene 
transcription through the recruitment of other molecular partners(Pérez-Salvia 
and Esteller 2017). One of the earliest bromodomain inhibitors that have been 
developed is  (+)-JQ1(Filippakopoulos, Qi et al. 2010), a drug that is well known 
for its ability to downregulate transcription of MYC and its genome wide 
dependent target genes through interfering with chromatin-dependent signal 
transduction to RNA polymerase by interfering with the acetyl-lysine recognition 
domains (bromodomains) of putative coactivator proteins involved in gene 
transcription(Delmore, Issa et al. 2011). Interestingly, the ability of (+)-JQ1 to 
target MYC epigenetically has put it forward as a promising drug that can 
override resistance to PI3K targeted inhibition (Stratikopoulos, Dendy et al. 2015, 
Stratikopoulos and Parsons 2016, Andrews, Singh et al. 2017).  
 
Therefore, I tested whether (+)-JQ1 would sensitize RP-B-01 cells to PI3K 
targeted inhibition. I tested different concentrations of LY3023414 and (+)-JQ1 
combination in vitro both in RP-B-01 and RP-B-02 cell lines. Using ComboSyn™, 
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a drug combination analysis program based upon the Chou-Talalay method for 
drug combination analysis (Chou 2010). I found the combination of LY3023414 
and (+)-JQ1 to be synergistic at all concentrations tested for both drugs with log 
combination index less than zero (Figure 44).  Indeed combined LY3023414 (+)-
JQ1 treatment was associated with suppression of feedback AKT 
phosphorylation and MYC stabilization that were induced upon therapeutic 
resistance in cells exposed to single agent LY3023414 for prolonged duration 





Figure 44: Combined PI3K/mTOR and BET inhibition sensitizes RP-
B-01 to LY3023414. A. RP-B-01 cells were treated with LY3023414 
and (+)-JQ1 in either as single agent or in combination in (1:1) ratio. 
At most concentrations tested the combination significantly sensitized 
cells to treatment in comparison to single agent.  Mean ± SD, n =3, 
representative results from at least triplicate experiments.  One way 
ANOVA, Tukey's multiple comparisons test, **P<0.01. B. The 
logarithmic CI index plot show most concentrations tested to have log 
















Figure 45: Combined PI3K/mTOR and BET inhibition is 
associated with downregulation of feedback AKT phosphorylation 
in RP-B-01 cells.  Feedback AKT phosphorylation is induced in 
RP-B-01 cells treated with single agent LY3023414 upon 
prolonged drug exposure (24H). When RP-B-01 cells are treated 
with LY3023414 combination, feedback AKT phosphorylation is 
attenuated along with MYC level.    
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However, this was not the case in the RP-B-02 cell line which is sensitive 
to LY3023414 as single agent. In this cell line, the combination of two drugs had 
either an additive or antagonistic effect for most of the concentrations tested with 





Figure 46: Combined PI3K/mTOR and BET inhibition is not 
synergistic in RP-B-02. A. RP-B-02 cells were treated with 
LY3023414 and (+)-JQ1 in either as single agent or in 
combination in (1:1) ratio. At most concentrations tested the 
combination did not provide RP-B-02 cells with significant 
therapeutic benefit.  Mean ± SD, n =3, representative results 
from at least triplicate experiments.  One way ANOVA, Tukey’s 
multiple comparisons test, **P<0.01. B. The logarithmic CI index 
plot show most concentrations tested to have log CI equal to or 
more than zero indicating either an additive or antagonistic 
effect. 
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C.9. BET inhibition sensitizes RP-B-01 to LY3023414 but not cisplatin 
Next I wanted to test whether the ability of (+)-JQ1 to sensitize RP-B-01 to 
treatment is specific to PI3K targeted inhibition or relevant to alternative 
treatments such as cisplatin. RP-B-01 is also resistant to cisplatin (Ciamporcero, 
Shen et al. 2016, Wei, Chintala et al. 2016); the mainstay of therapy in bladder 
cancer patients (Kamat, Hahn et al. 2016, Lobo, Mount et al. 2017). Interestingly, 
I did not find the cisplatin- (+)-JQ1 combination to be synergistic at any 
concentrations tested (Figure 47), indicating that bromodomain targeting by (+)-
JQ1 sensitizes RP-B-01 to LY302414 but not cisplatin. This provides a proof of 
concept that the benefit conferred to RP-B-01 cells by bromodomain targeting is 






Figure 47: BET inhibition sensitizes RP-B-01 to LY3023414 but 
not cisplatin. A. RP-B-01 cells were treated with cisplatin and (+)-
JQ1 either as single agent or in combination in (1:1) ratio. At all 
concentrations tested the combination was not better than cisplatin 
single agent. Mean ± SD, n =3, representative results from at least 
triplicate experiments.  One way ANOVA, Tukey’s multiple 
comparisons test, P> 0.5. B. The logarithmic CI index plot show 
most concentrations tested to have log CI equal to or more than 
zero indicating either an additive or antagonistic effect 
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C.10. ERK inhibition does not sensitize RP-B-01 to LY3023414 treatment 
Since we found MAPK signaling to be significantly activated in RP-B-01 in 
comparison to RP-B-02, I wanted to determine whether combined ERK 
(LY3214996) (Bhagwat, McMillen et al. 2017, Zhao, McMillen et al. 2017, Kidger, 
Sipthorp et al. 2018) and PI3K inhibition (LY3023414)(Smith, Mader et al. 2016) 
would overcome resistance to PI3K targeted therapy in RP-B-01 similar to what I 
observed with (+)-JQ1. Interestingly however, the synergy that I observed with 
(+)-JQ1 was not evident with ERK inhibitor LY3214996 (Figure 48) despite 
feedback activation that I have observed upon therapeutic resistance (Figure 
42A). This implies that while RP-B-01 cells escape PI3K inhibition by MAPK 
activation, it is probably stabilization of MYC that plays the key role in driving 
resistance and therefore the main event that is worth co-targeting to provide a 































Figure 48: ERK inhibition does not sensitize RP-B-01 to LY3023414 
treatment. A. RP-B-01 cells were treated with LY3023414 and 
LY3214996 either as single agent or in combination in (1:1) ratio. At 
all concentrations tested the combination was not better than 
LY3023414 single agent. Mean ± SD, n =3, representative results 
from at least triplicate experiments.  One way ANOVA, Tukey’s 
multiple comparisons test, P> 0.5. B. The logarithmic CI index plot 
show most concentrations tested to have log CI equal to or more than 
zero indicating either an additive or antagonistic effect. 
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C.11. Development of alternative MIBC PDX models for drug testing  
In order to validate our data in alternative models in vivo; I developed and 
characterized 9 additional PDX models (Table 3). Using cytokeratin staining 
(Cytokeratin 20 and 5/6), I identified the subtype of each model (Figure 49). The 
use of Cytokretain staining to identify subtype was verified by comprehensive 
genomic analysis in collaboration with Dr. David McConkey at the Johns Hopkins 
school of Medicine (Figure 50). Next, using Taqman™ PCR based mutation 
detection assay, I screened the models for PIK3CA mutation status. Interestingly 
I found IU68T to be a luminal-like model that carries a missense PIK3CA 





Table 3: List of novel bladder cancer PDX models developed 




Figure 49: Development and characterization of basal-like 
MIBC PDX models.  Representative IHC for Cytokeratins 20 
and 5/6. Cytokeratin staining identified IU-5T as novel basal-
like MIBC PDX models while IU-80T, IU68T and IU-16T 




Figure 50: RNA-Seq analysis confirms IHC detected subtype of 
novel IU PDX models. Representative heat map depicting 
expression levels of select basal and luminal markers in novel 
IU bladder cancer PDX models. RNA-seq analysis confirms IU-
3Tand IU-5T to behave as basal-like tumors while IU-




   
Figure 51: IU-68T is a novel Luminal like PIK3CA E545K 
mutant Bladder PDX model (RP-B-02 like). A. Screening of IU 
PDX mdoels for PIK3CA E542K mutation. Red solid line 
represents ΔCT cut off value for detection of mutation. B. 
Screening of IU PDX mdoels for PIK3CA E545K mutation. Red 
solid line represents ΔCT cut off value for detection of 
mutation. CT value below cutt off is indicative of positive 








Targeted therapy provides select patients with maximal therapeutic benefit 
with fewer side effects compared to conventional chemotherapy. However, so far 
targeted therapy has not found its way in the management of bladder cancer 
where conventional chemotherapy (i.e. cisplatin) continues to be the standard of 
care (Kamat, Hahn et al. 2016). This is largely attributed to the lack of predictive 
molecular stratification of patients in bladder cancer clinical trials (Shah, 
McConkey et al. 2011). A recent attempt at comprehensive molecular 
characterization of bladder cancer has identified PI3K pathway as one of the 
most frequently dysregulated signaling pathways in this disease; where PIK3CA 
(HD) mutations are the most significant (Knowles, Platt et al. 2009, Platt, Hurst et 
al. 2009, Shah, McConkey et al. 2011, Network 2014). Despite the high rate of 
mutations in this pathway in bladder cancer as well as other tumors, therapies 
targeting this pathway are still facing key challenges in the clinical setting  
(Fruman & Rommel, 2014; Massacesi et al., 2016). While PIK3CA HD mutations 
are the most significant alterations in this pathway in bladder cancer, largely 
mTOR inhibitors were exclusively used in clinical trials despite the absence of 
mTOR mutations in this disease (Houédé and Pourquier 2015). Only two bladder 
cancer trials are utilizing novel PI3K inhibitors (Munster, Aggarwal et al. 2015) 
and (NCT01551030). Therefore, the significance of PIK3CA HD mutations in 
terms of predicting therapeutic response is yet to be determined. 
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Bladder cancer however is a highly complex disease with high incidence 
of mutations that is only exceeded by melanoma and lung cancer (Kim, Akbani et 
al. 2015). In the light of the recent comprehensive characterization of bladder 
cancer into distinct molecular subtypes(Choi, Porten et al. 2014, Damrauer, 
Hoadley et al. 2014, Network 2014, Robertson, Kim et al. 2017), it is crucial to 
understand the therapeutic significance of PIK3CA HD mutations in the context 
of distinct molecular subtypes (i.e. basal-like and luminal-like tumors).  
  
Preclinical data and data from phase I and II clinical trials suggest that 
PIK3CA mutation status can predict response to PI3K targeted therapy (Janku, 
Tsimberidou et al. 2011, Janku, Wheler et al. 2013). However, there is also data 
to suggest that either response or resistance to PI3K targeted inhibition is rather 
a function of tumor subtypes as is the case of triple negative basal-like breast 
cancer. In basal-like breast cancer PI3K/mTOR  signaling  has been suggested 
to play a key role(Massihnia, Galvano et al. 2016) in therapeutic resistance to 
PI3K targeted inhibition which was linked to subtype specific alterations such as 
MYC amplification,  alternative feedback signaling and innate tumor 
heterogeneity(Dey, Leyland-Jones et al. 2015, Matkar, Sharma et al. 2015, 
Massihnia, Galvano et al. 2016). Interestingly, classification of MIBC into distinct 
molecular subtypes was carried out in the light of well-established gene 
expression profiles of breast cancer subtypes (Damrauer, Hoadley et al. 2014); 
suggesting that subtype can also be a player in driving resistance to PI3K 
targeted inhibition.  
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We characterized two MIBC PDX models developed in our lab  (RP-B-01 
and RP-B-02) which are of distinct molecular subtypes (basal-like and luminal-
like respectively) and carry distinct PIK3CA HD mutations (E542K and E545K 
respectively) to respond differently to multiple dual PI3K/mTOR inhibitors (i.e. 
LY3023414) where RP-B-01 was resistant while RP-B-02 was sensitive to 
treatment. To pinpoint whether resistance to PI3K targeted inhibition is a function 
of PIK3CA mutation status, subtype or a combination of both, we underwent 
comprehensive GSEA of TCGA data in conjunction with RNA-seq data from our 
two PDX models to determine the signaling pathways that are significantly 
distinct between E542K and E545K mutant tumors irrespective of subtype.    
 
We found E542K mutant tumors to be enriched with glycolytic pathways 
that are known to have a much higher turnover of intermediates for 
macromolecular biosynthesis and redox homeostasis despite being less efficient 
than oxidative phosphorylation (OXPHOS)(Wong, Qian et al. 2017).  In 3D 
culture, we found that E542K mutant bladder cancer spheroids trended towards a 
higher uptake of hypoxia marker LOX-1. Moreover, when we transfected isogenic 
HEK cells with either E542K or E545K mutant PI3KCA and found the E542K 
mutation status to be associated with therapeutic resistance similar to what we 
have observed in our RP-B-01 model implying that mutation status can play a 
key role in determining  treatment response.  
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We found that resistance to PI3K targeted inhibition in RP-B-01 PIK3CA 
E542K mutant model coincided with stabilization of MYC which is known to 
mediate the transcription of almost all the genes involved in glycolysis and 
glutaminolysis where it promotes the shuttling of glycolytic intermediates to 
macromolecular biosynthetic pathways (Osthus, Shim et al. 2000, Priolo, Pyne et 
al. 2014, Stine, Walton et al. 2015). Recent reports investigating resistance to 
PI3K targeted therapy have proposed sustained bromodomain (BRD4) binding at 
chromatin regulatory regions of receptor tyrosine kinases and MYC as key 
drivers of therapeutic resistance (Stratikopoulos, Dendy et al. 2015, 
Stratikopoulos and Parsons 2016). Indeed when we combined dual PI3K/mTOR 
inhibitor (LY3023414) and bromodomain inhibitor (JQ1), we found significant 
synergy and we were able to overcome resistance to PI3K targeted inhibition.   
 
Importantly, we were not able to harness this therapeutic benefit when we 
combined JQ1 with cisplatin or when MAPK and PI3K signaling pathways were 
co-targeted. Taken together, this provides proof of concept that the synergy was 
specific to overcoming resistance to PI3K targeted inhibition induced downstream 
by activation of MYC.  Although our GSEA and confirmatory q-PCR experiments 
in HEK and bladder cancer cells show that E542K mutation induce MYC 
expression and its downstream glycolytic metabolic rewiring significantly more 
than E542K mutation, it is not yet mechanistically clear  why that is the case. Our 
future goal is to investigate whether this is driven by differential RAS binding 
affinity to the PI3Kα protein that harbors HD mutations.   
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A key limitation of our study is lack of further confirmatory in vivo data in 
alternative PDX models in order to provide a stronger predictive rationale for 
selection of patients who can benefit from PI3K targeted therapy in clinical trials. 




CHAPTER V: CHARACTERIZATION OF THE EPIGENETIC SIGNATURE OF 
TWO BIOLOGICALLY DISTINCT BLADDER CANCER MODELS 
A. Chapter Summary 
Two bladder patient derived xenograft (PDX) models developed in our lab 
carry PIK3CA activating HD mutations. One model is responsive to treatment 
with dual PI3K/mTOR inhibitor LY3023414 (RP-B-02; PIK3CA E545K mutant) 
while the other model (RP-B-01; PIK3CA E542K mutant) is resistant, as 
previously described in chapters III and IV. Interestingly, these two models are of 
distinct bladder cancer subtypes, where RP-B-01 is basal-like compared to RP-
B-02 which is luminal-like. We hypothesized that distinct PIK3CA HD mutations 
(E545K and E542K) could play a potential role in driving resistance to therapy, 
driven by two mutually exclusive epigenetic loss of function mutations; KMT2D 
and KDM6A, which were detected in RP-B-01 and RP-B-02 respectively(Wei, 
Chintala et al. 2016). Therefore we set out to compare the differential DNA 
methylation profiles between two models and investigate whether it influences 
gene expression through protein-protein interaction (PPI) network in association 
with mutated genes detected in each PDX model. DNA methylation analysis 
recognized 14,944 differentially methylated regions (DMRs) (q < 0.05) locating 
within 4 kb upstream to 500 bp downstream of gene transcription start sites 
(TSSs). About one third (35.3%) DMRs were hypermethylated in B01 compared 
to B02. Interestingly; most differentially expressed genes (DEGs) (64.5%) 
associated with DMRs exhibited positive correlation between gene expression 
change and corresponding DNA methylation variation. However, DMRs 
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negatively correlated with expression of associated genes were overrepresented 
in proximity to TSS. Importantly, PPI network of genes with nonsense mutation 
specific to RP-B-01 and RP-B-02 (i.e. KMT2D and KDM6A respectively) were 
distinct with little overlap observed. They showed significantly different ratios of 
DEGs and DMRs, suggesting a potential role in driving phenotypic distinction and 
differential therapeutic response. Overall, we found that both models have 
distinct gene expression and DNA methylation profile. In the previous chapter we 
proposed potential role of distinct PIK3CA mutations in predicting response to 
treatment. However, taking into account the complexity of subtype related 
signaling and other key mutations in both PDX models; we propose that 
resistance could potentially be predicted by the complex interplay of distinct 
PIK3CA mutations with distinct gene expression profile that is epigenetically 
driven in PIK3CA mutant bladder cancer. 
 
B. Background and Rationale 
Epigenetic alterations, which include aberrant DNA methylation as well as 
mutations in chromatin remodeling genes, occur in 89% of cases (Network 
2014). Global and gene specific alterations in DNA methylation in MIBC have 
been extensively studied primarily to better diagnose and prognosticate 
patients(Mikeska and Craig 2014). However, in the light of the newly proposed 
MIBC subtypes, the role of epigenetic changes, mainly alterations in DNA 
methylation, in driving the fate of the basal bladder cancer cell that could partly 
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lead to distinct subtypes and possibly predict treatment response remain to be 
understood (Mikeska and Craig 2014, Kitchen, Bryan et al. 2016). 
 
Two bladder cancer patient derived xenograft (PDX) models developed in 
our lab (RP-B-01 and RP-B-02) carry distinct PIK3CA activating HD mutations. 
We previously reported gene expression profile for those models(Wei, Chintala et 
al. 2016) and found them to be representative of basal-like and luminal-like 
subtypes respectively. Importantly; they are also distinct in terms of treatment 
response, where one model is responsive to treatment with either dual 
PI3K/mTOR inhibitor LY3023414 (RP-B-02; PIK3CA E545K mutant) or cisplatin 
while the other model (RP-B-01; PIK3CA E542K mutant) is resistant to both. 
Here we set out to compare the differential DNA methylation profiles between 
two models and investigate how it influences gene expression through protein-
protein interaction (PPI) network in association with mutated genes detected in 
each PDX model. The purpose is to identify potential players that drive 
resistance to treatment. 
 
C. Results 
C.1. A significant number of DMRs exist between RP-B-01 and RP-B-02 
In previous genome wide profiling of RP-B-01 and RP-B-02 models, we 
identified differentially expressed genes (DEGs) between these two models and 
found them to be equivalent to 6.18% of expressed genes. Looking at genome 
wide DNA methylation in this study, we identified total 354,493 differentially 
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methylated regions (DMRs) by MethylAction (q < 0.05), 42.5% of which were 
hypermethylated in B01 compared to B02. 14,944 DMRs locate from upstream 4 
kb to downstream 500 bp of 9,663 genes, 35.3% of which were hypermethylated 
in B01 (Figure 52A). Interestingly, a significant number of genes had mixed 
signals within different regions in the gene body; that are yet to be functionally 
interrogated (Figure 52B).  We subsequently integrated the DNA methylation 
dataset with gene expression dataset to determine the ratio between DEGs and 
DMRs in both models. We identified a total of 369 genes with DMRs and we 
found DEGs to be significantly hypermethylated in RP-B-01 compared to RP-B-







Figure 52: Significant number of differentially methylated 
regions exists in bladder cancer PDX models. A. 14,944 DMRs 
locate from upstream 4 kb to downstream 500 bp of 9,663 
genes, 35.3% of which were hypermethylated in B01. B. 
Signals of differential methylation between two models were 
mixed and not exclusive to the Transcription start site (TSS) 




Figure 53: Ratio of DEGs in different groups of genes.  
Genes enriched with DMRs show significant differential 
expression between two models when compared to overall 
gene expression. In RP-B-01, DEGs with DMRs are 
significantly hypermethylated (High M) compared to RP-B-02. 
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The dogma in the field is that CpG island methylation generally correlates 
with gene repression and regulation of tissue specific gene expression (Deaton 
and Bird 2011). However, recent reports challenge this concept and show that 
both positive and negative correlation between DNA methylation and gene 
expression exist and provide multiple levels of regulation of gene 
expression(Wan, Oliver et al. 2015). We investigated the methylation status of 
well recognized genes that have been proposed to be markers of basal-like (i.e. 
TP63, KRT6) and luminal like (i.e. PPARG, FOXA1, HDAC9) subtypes(Choi, 
Porten et al. 2014, Damrauer, Hoadley et al. 2014, Eriksson, Rovira et al. 2018).  
 
We found those genes to be generally negatively regulated by 
methylation, where basal genes were hypermethylated in RP-B-02 in comparison 
to RP-B-01 and suppressed (Figure 54) while luminal genes were 
hypomethylated in RP-B-02 compared to RP-B-01 and overexpressed (Figure 
55). Interestingly, this pattern was not exclusive to methylation at the promoter 
region of each gene, but also included methylation signals that were detected in 
gene body (Figure 54, 55).  
 
However, looking globally at DEGs between the two models, we found 
that most DEGs (64.5%) with DMRs show positive correlation between gene 
expression change and methylation change (Figure 56). In RP-B-01 model, 
DMRs with higher methylation level and lower gene expression level were 
enriched in proximity to TSS (Figure 56B).  
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Figure 54: Methylation status of genes that define basal subtype 
of bladder cancer. CK6 and CK16; markers of basal like subtype 
of bladder cancer are hypermethylated in RP-B-02 compared in 
RP-B-01 and gene expression is lower; however P63 which is 




Figure 55: Methylation status of genes that define luminal 
subtype of bladder cancer.  Markers of luminal like subtype in 
bladder cancer (i.e. FOXA1, PPARG) are hypomethylated in 










Figure 56:  Significant percentage of DEGs with DMRs show positive 
correlation between methylation change and gene expression. A. 
Scatter plot of fold change (FC) in gene expression (B02/B01) and FC 
of methylation changes (B02/B01). The table is showing unique 
direction of methylation changes in 369 DEGs. 154 and 84 genes in 
RP-B-01 and RP-B-02 respectively show positive correlation between 
gene expression and DNA methylation. B. Graphical representation of 
methylation changes in RP-B-01 in relation to gene expression.  
DMRs with higher methylation level and lower gene expression level in 
B01 were enriched in proximity to TSS.  GE= gene expression, M= 
methylation, FC= fold change. DEGs= differentially expressed genes, 
DMRs= differentially methylated regions.  
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C.2. Positive DMRs play a key role in bladder differentiation and development 
Genes associated with positive DMRs are enriched with negative 
regulators of key developmental and regulatory functions(Wan, Oliver et al. 
2015). Therefore, we performed Gene ontology (GO) analysis on genes 
associated with positive or negative DMRs. We identified four functionally distinct 
groups of genes in both bladder cancer models (Figure 57); interestingly we 
detected consistent findings with a previous report(Wan, Oliver et al. 2015); 
where positive DMRs were enriched with negative regulation of cell 
activation/cell-cell adhesion/cellular process/cell differentiation/leukocyte 
activation/biological process . This supports the idea that a novel model of gene 
expression regulation exists, where DNA methylation indirectly suppresses the 






















Figure 57: Four groups of DEGs identified based on 
correlation between gene expression and methylation 
changes. Representative heat map of 4 groups of DEGs 
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C.3. Genes interacting with mutated genes are more enriched in DEG, DMRs, 
and DEG with DMR sets than others 
In order to understand the functional significance of DEGs and DMRs 
between two models, we sought to investigate the complex interaction network of 
DEGs with DMRs in relation to mutant genes in both models. Out of total 1,899 
somatic mutations identified in our previously published analysis (Wei, Chintala 
et al. 2016), 919 (48%) were B01-specific.1,324 mutations matched to expressed 
genes, 675 (51%) of which were B01-specific (p = 1.1E-4, compared to all 
mutations). In line with the distinct subtype and therapeutic response of each 
model, we found the mutant genes to be functionally distinct, where B01 specific 
mutant genes were enriched with abnormalities in DNA repair while RP-B-02 
specific mutations were enriched with cell-adhesion and morphogenesis related 
pathways (Figure 58A). While no mutation was covered by DMR; PPI network 
showed significantly stronger perturbation when taking into account the 






Figure 58: Genes with mutations in each model have distinct 
functions. A. Representative graph of the common and distinct 
mutations between both models and their functional relevance. B. PPI 
network with stronger perturbation on difference of gene expression 
and methylome between two types of mutations 
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C.4. Nonsense and Missense mutations drive distinct PPI interaction network 
with DEGs and DMRs  
Loss of function mutations in a large number of chromatin modifying 
genes are highly enriched in bladder cancer (89% of cases). Most notably are 
mutations in KMT2D and KDM6A which are mutually exclusive, indicating either 
a redundant or a synthetically lethal effect of combined loss (Gui, Guo et al. 
2011, Kim, Sharma et al. 2014, Network 2014). Both KMT2D and KDM6A are 
members of the complex of proteins associated with Set1 (COMPASS) family, 
where KMT2D acts as H3K4 methyl transferase while KDM6A acts as a H3K27 
demethylase (Figure 59). Opposing roles played by the members of COMPASS 
family and members of other epigenetic families such as the polycomb 
repressive complex 1 and 2 (PRC1 and PRC2) maintain the epigenetic balance 
(Piunti and Shilatifard 2016). Earlier reports have suggested significant 
prevalence of KMT2D mutations in non-papillary high-grade bladder cancer as 
opposed to papillary low-grade tumors where mutations in demethylases (i.e. 
KDM6A) are more prevalent (Gui, Guo et al. 2011, Kim, Akbani et al. 2015, 
Kamat, Hahn et al. 2016). This dichotomy resonates with the mutual exclusivity 
observed in the TCGA data with regard to mutations in those two chromatin 
modifying genes (Network 2014). However, a conclusive relation between 
KMT2D and KDM6A mutations and basal and luminal subtypes of bladder 





Figure 59:  The coordinated function of COMPASS and PRC family 
members to maintain epigenetic balance. KDM6A (COMPASS 
family member) counteracts the H3K27me2/3 repressive marks 
deposited by PRC2 (i.e. EZH2). Subsequently, KMT2D (COMPASS 
family member) can function as a methyltransferase toward lysine 4 
on histone H3, which subsequently favors the H3K27ac deposition 
by the histone acetyltransferases (HATs) CBP/p300. This is thought 
to positively regulate, when stimulated, the expression of genes 
transcriptionally poised because of the restrictive presence of PRC2 
activity. The numbered circles are intended to highlight the 
coordination of steps. Adapted from (Piunti and Shilatifard 2016). 
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On our end, when we closely examined missense mutations in both 
models, we found overlapping mutations that involved the histone 
methytransferase complex (ACTB/CHD8/KMT2D) (Figure 60). Interestingly 
however; nonsense mutations were mutually exclusive in both models; where 
RP-B-02 was enriched with nonsense mutations in both protein acetylation 
complex (KMT2A/NAA15/SRCAP/TRRAP) and histone methyltransferase 
complex (KDM6A/KMT2A/TAF6) (Figure 62).While this observation resonates 
with the distinct subtypes of both models that could partly be epigenetically 
driven; its functional significance in terms of distinct therapeutic response is yet 
to be determined.  
 
The dichotomy was also clear when we compared the PPI network of 
each mutation subset.  While the PPI network of missense mutations was 
enriched with DMRs in RP-B-01 (Figure 61), the opposite was true for nonsense 
mutations where RP-B-02 had significantly higher DMRs and lower DEGs in 





Figure 60: Genes with missense mutation in two models have 
distinct functions. Graphical representation of the functional 
relevance of missense mutations in each model.  Missense 
mutations in the histone methytransferase complex 




Figure 61: Differential enrichment for PPI network of genes with 
missense mutations. Proteins interacting with genes carrying 
missense mutations are more enriched in DEGs in RP-B-B02; 






Figure 62: Genes with nonsense mutation in two groups have distinct 
functions. Graphical representation of the functional relevance of 
nonsense mutations in each model. No overlap exists between two 
models with respect to nonsense mutations. RP-B-02 is enriched in 
























Figure 63: Differential enrichment for PPI network of genes with 
nonsense mutations. Opposite to the trend observed in figure 61; 
proteins interacting with genes carrying nonsense mutations are 
enriched with DMRs in B02 yet enriched with DEGs in B01. 
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C.5. KMT2D/KDM6A PPI network is subtype related 
We subsequently interrogated the PPI network for genes that specifically 
interact with KMT2D and KDM6A mutations in RP-B-01 and RP-B-02 model 
respectively. KDM6A nonsense mutation in RP-B-02 mostly interacted with 
genes at their enhancer regions; which are known to be crucial for cell type 
specific gene expression and regulation of differentiation (Ong and Corces 2011, 
Lee, Wang et al. 2013, Lee, Park et al. 2017). This resonates with our GO 
analysis; which showed that RP-B-02 specific mutations are enriched with 
differentiation and morphogenesis related pathways (Figure 58, 60).  
 
On the other hand the PPI network for KMT2D showed significant 
interaction with Nuclear Receptor Subfamily 1 Group H Member 3 (NR1H3) (also 
known as LXRA)(Figure 64). NR1H3 is known to regulate fatty acid synthase 
(FASN) expression(Joseph, Laffitte et al. 2002); which plays a key role in 
regulation of lipid homeostasis. FASN is overexpressed in RP-B-01 compared to 
RP-B-02 and is induced upon resistance to LY3023414 in a time dependent 
manner (Figure 27). Collectively, these findings support the role of metabolic shift 
influenced by both subtype and mutation status in driving resistance to PI3K 
targeted therapy in the RP-B-01 model.  
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Figure 64: PPI network of mutated chromatin modifying genes in RP-
B-01 and RP-B-02. A. PPI network of NR1H3 (STRING DATABASE) 
shows that NR1H3 activates FASN. The interaction score is set at high 
confidence (0.7). KEGG pathway analysis related to this interaction 
network predicts the following pathways (in order of significance) as the 
most significantly involved pathways in this interaction (Fatty acid 
biosynthesis, Fatty acid metabolism, PPAR signaling, AMPK signaling) 
B. Most significantly interacting proteins with KMT2D which are 
predicted to carry missense mutation in basal-like RP-B-01. NR1H3 is 
predicted to have the most significant interaction. **P<0.01. C. PPI 
network of KDM6A which is predicted to carry nonsense mutation in 
luminal-like RP-B-02.  
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D. Discussion 
DNA methylation has been previously investigated in bladder cancer 
mainly to enable early detection and monitoring of disease recurrence in urine 
sediments in order to avoid the economic and clinical burden associated with 
routine cystoscopy(Barocas, Globe et al. 2012). However, in our study we are 
proposing a novel insight into bladder cancer DNA methylome in conjunction with 
newly characterized chromatin modifying genes that are highly prevalent in 
bladder cancer. Novel subtypes have been recently proposed for MIBC; therefore 
our novel subtype distinct bladder cancer PDX models represent an invaluable 
tool to test subtype specific epigenetic signature. 
 
Previous research has shown that high grade bladder cancer is enriched 
with DNA hypermethylation in comparison to lower grade tumors(Olkhov-Mitsel, 
Savio et al. 2017). We observed a similar trend in basal-like treatment resistant 
RP-B-01 model; where DEGs with DMRS were significantly hypermethylated 
compared to luminal-like RP-B-02 model. However, in this study we propose a 
novel concept; where we show that a significant fraction of the hypermethylated 
DMRs observed in the RP-B-01 model positively correlate with gene expression.  
 
This corroborates a previous report that showed that a significant fraction 
of tissue specific DMRs positively correlate with gene expression level and are 
enriched with negative regulators of gene expression(Wan, Oliver et al. 2015). 
While they were not able to predict this 2-layer regulation when they analyzed 
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cancer specific DMRs in colon cancer(Irizarry, Ladd-Acosta et al. 2009, Wan, 
Oliver et al. 2015); our bladder cancer study showed that positive DMRs were 
significant and also enriched in negative regulators of pathways involved with cell 
differentiation and tissue development. This could possibly be explained by RP-
B-02 specific nonsense mutations in both protein acetylation complex 
(KMT2A/NAA15/SRCAP/TRRAP) and histone methyltransferase complex 
(KDM6A/KMT2A/TAF6) which were found to preferentially interact with enhancer 
regions that are known to play key role in tissue specific development. However 
this observation warrants further investigation in order to better understand the 
complex interplay between histone and DNA methylation and how this guides 
subtype specific development. 
 
We also interrogated the PPI network specific to distinct mutant chromatin 
modifying genes identified in both models and we found a strong interaction with 
genes involved in lipid homeostasis; mainly (NR1H3; PPARG). These genes 
were significantly upregulated in RP-B-02 compared to RP-B-01 model, which 
had a higher level of fatty acid synthase (FASN). Interestingly, upon prolonged 
treatment with dual PI3K/mTOR inhibitor LY414 which coincided with resistance; 
FASN was induced pointing toward a metabolically driven mechanism of 
resistance that we proposed as mechanism of resistance to PI3K therapy in 
PIK3CA E542K mutant bladder cancer.  The novelty however, lies in the 
possibility that this could be driven by cross talk between highly prevalent 
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mutations in chromatin modifying genes and PIK3CA which frequently co-occur 
together. 
 
Overall, our findings present a novel concept of multilayered regulation of 
gene expression by DNA methylation. A main limitation of our study is lack of 
DNA methylation data from normal bladder tissue which would provide deeper 
insight into the functional significance of this regulation. While targeting specific 
molecular perturbations has not been successful in the bladder cancer field so 
far, a better understanding of specific bladder cancer subtypes that could be 
driven by an epigenetic signature can eventually lead to the long awaited 
advancement in the management of this disease. 
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CHAPTER VI: DISCUSSION 
A. Summary and Discussion 
A.1. MIBC: Current management and its limitations. 
The standard of care in MIBC is comprised of neoadjuvant cisplatin based 
chemotherapy followed by radical cystectomy and bilateral pelvic 
lymphadenectomy (Kamat, Hahn et al. 2016). 
 
However, cisplatin based treatment is associated with high dose-limiting 
toxicities including; increased risk of hematological adverse events and renal 
adverse events.   Additionally, many patients eventually develop resistance to 
cisplatin and become cisplatin–refractory(Chou, Selph et al. 2016). 
 
Several immune checkpoint inhibitors that target programmed cell death 
protein 1 (PD1), its ligand PDL1, and cytotoxic T lymphocyte-associated protein 4 
(CTLA4) have already been approved for first or second line use in bladder 
cancer management (Sundararajan and Vogelzang 2015). With respect to 
targeted therapy, agents targeting different pathways (i.e. VEGF, EGFR, and 
PI3K/mTOR) were used, albeit in small nonrandomized trials. Modest to non-
survival benefit was seen with these agents. This unfavorable outcome was 
attributed to  lack of adequate patient population selection on trials (Sverrisson, 
Espiritu et al. 2013). 
 
177 
Recently however, novel molecularly based classification for muscle 
invasive bladder cancer was proposed classifying MIBC into different 
subtypes(Choi, Porten et al. 2014, Network 2014, Robertson, Kim et al. 2017) 
that are thought to reflect the hallmarks of breast cancer biology(Damrauer, 
Hoadley et al. 2014). Additionally, key molecular aberrations in the disease were 
identified. The goal is to ultimately guide better patient selection on clinical trials 
to decrease attrition and provide patients with new personalized treatment 
options. Interestingly, anti-EGFR therapy which has previously failed in clinical 
trials (Petrylak, Tangen et al. 2010, Wong, Litwin et al. 2011) was associated with 
significant therapeutic benefit in basal-like MIBC in a pre-clinical study that was 
guided by novel bladder cancer subtypes (luminal-like and basal-like) 
(Rebouissou, Bernard-Pierrot et al. 2014). 
 
The PI3K/AKT/mTOR is dysregulated in 42% of bladder cancer cases, 
25% of these cases are due to activating PIK3CA mutations(Network 2014, 
Robertson, Kim et al. 2017). PI3Ks are heterodimeric lipid kinases in which 2 
main gain of function mutations have been characterized, either kinase domain 
(KD) mutations (H1047R) or helical domain (HD) mutations (E545K, E542K). HD 
mutations are the most common activating PIK3CA mutations in bladder cancer, 
unlike other solid tumors where KD mutations are more common(Knowles, Platt 
et al. 2009, Platt, Hurst et al. 2009) However, the role of these mutations in 
determining response to therapy remains to be elucidated. Understanding the 
molecular determinants of response to PI3K pathway targeted therapeutics will 
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pave the way for a more personalized therapeutic approach that will improve 
success rates in clinical trials. 
 
A.2. Development and Characterization of two PIK3CA mutant MIBC PDX 
models 
The centrality of PI3K/mTOR signaling to bladder cancer pathogenesis 
(Knowles, Platt et al. 2009, Platt, Hurst et al. 2009) highlights the need for 
developing MIBC models which harbor common pathway aberrations in order to 
develop effective treatment for targeting this pathway in patients. 
 
In our lab, we developed PDX models from patient cystectomy 
specimens. Using high through put genomic profiling in conjunction with patient 
characteristics and unique histological features of each tumor used, we 
characterized two MIBC PDX models. Interestingly, we found the two models to 
harbor distinct PIK3CA HD mutations, where RP-B-01 was PIK3CA E542K MUT, 
while RP-B-02 was PIK3CA E545K MUT. Additionally, I found the models to be 
representative of two distinct bladder cancer subtypes, basal-like and luminal-like 
respectively. This sets those models as valuable tools for testing the interplay 
between mutation status and subtype in driving resistance/response to PI3K 
targeted inhibition. 
 
Interestingly, I found the two models not only distinct with respect to 
mutation status and subtype, but also distinct in therapeutic response, where 
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basal-like PIK3CA E542K MUT RP-B-01 was resistant to dual PI3K/mTOR 
targeted inhibition while luminal-like PIK3CA E545K MUT RP-B-02 was sensitive.  
These findings provided the rationale for dissecting determinants of response to 
PI3K targeted inhibition. 
 
A.3. PIK3CA E542K mutation confers resistance to PI3K targeted therapy 
In order to determine whether resistance to PI3K targeted therapy is a 
function of mutation status or more complexly driven by cross talk between 
PIK3CA mutation status and unique genetic/epigenetic signature of each 
subtype; we analyzed publicly available RNA-seq data from TCGA in conjunction 
with RNA-seq data from our models (RP-B-01/02) to determine the pathways that 
are significantly enriched in PIK3CA E542K mutant tumors in comparison to 
E545K mutant tumors irrespective of subtype. Our analysis confirmed a 
differential signaling pattern that is driven by each mutation and which is mainly 
involved with a distinct metabolic profile where E542K mutant tumors are better 
equipped to undergo a glycolytic switch and utilize alternative nutrients to 
glucose such as fatty acids and amino acids. 
 
Next to confirming that mutation status per se drives distinct signaling 
pattern, we tested whether they are similarly distinct with respect to drug 
interaction.  Predictive in-silico analysis of LY3023414-PIK3CA binding predicted 
a differential mode of binding with each PI3KCA HD mutation. Using a scoring 
system that ranks multiple forces that are known to be involved in ligand-
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substrate interaction such as hydrogen bonds and electromagnetic forces, we 
found that drug-protein binding is tighter with the PIK3CA E545K mutation as 
opposed to the E542K mutation which behaved more similar to the WT protein. 
 
In order to confirm that PIK3CA mutation status can independently 
predict response to PI3K targeted therapy, I developed isogenic HEK cells that 
express either WT or mutant (E542K; E545K) PIK3CA. I monitored the 
oncogenic potential of each mutation by observing cell growth in monolayer and 
3D culture and interestingly found that E542K mutation confers a significant 
growth advantage to HEK cells in comparison to E545K mutation. I tested 
therapeutic response to LY3023414 and found cells transfected with E542K 
mutant PIK3CA to be significantly more resistant to treatment compared to cells 
transfected with E545K mutant PIK3CA. Therapeutic resistance was associated 
with sustained AKT phosphorylation in PIK3CA E542K mutant cells. 
 
PIK3CA HD mutations are thought to behave similarly since they are both 
RAS dependent unlike PIK3CA kinase domain (H1047R) mutation which is 
dependent on P85 binding (Miled, Yan et al. 2007, Zhao and Vogt 2008). 
However our data show that they induce distinct downstream signaling pattern as 
well as characteristic interaction profile with the drug that induces resistance with 
PIK3CA E542K but not the E545K mutation. This also opens the possibility not 
only for distinct interaction with LY3023414 but also for differential capacity in 
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protein-protein interaction and therefore in their ability to induce feedback 
signaling. 
 
Providing a proof of concept that distinct PIK3CA HD mutation can be 
predictive of therapeutic response to PI3K targeted therapy is very significant for 
the bladder cancer field where HD mutations represent that majority of mutations 
found in PIK3CA mutant bladder tumors unlike other tumors where kinase 
domain mutations are more common(Knowles, Platt et al. 2009, Platt, Hurst et al. 
2009). 
 
A.4. Promising drug combinations to overcome resistance to PI3K targeted 
inhibition 
The main goal of dissecting mechanisms of therapeutic resistance is to 
identify better combinatorial treatment approaches that can target alternative 
feedback signaling induced upon resistance. 
 
Our mutation specific TCGA based pathway analysis showed that E542K 
mutation status is associated with significant upregulation of G- protein coupled 
signaling in addition to activation of MAPK-ERK signaling. Indeed I found that in 
RP-B-01 (PIK3CA E542K MUT) but not in RP-B-02 cells (PIK3CA E545K MUT), 
ERK phosphorylation is induced upon resistance to LY3023414. Interestingly, 
feedback activation of MAPK signaling was associated with stabilization of MYC. 
MYC is a well-known player in resistance to PI3K targeted therapy especially in 
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the context of PIK3CA mutation(Dey, Leyland-Jones et al. 2015). Moreover, it is 
known to be play a key role in the metabolic rewiring of cancer cells in order to 
switch to glycolytic signaling and more efficiently utilize intermediates for 
macromolecular biosynthesis (Stine, Walton et al. 2015, Wong, Qian et al. 
2017)as is observed in E542K mutant tumors. 
 
Based on the distinct signaling that is associated with E542K mutation 
status, I tested a number of drug combinations to identify a promising approach 
that can overcome resistance to PI3K targeted inhibition. Interestingly, I only 
found bromodomain (BET) targeting (Brd4) by JQ1 to sensitize RP-B-01 cells to 
LY3023414, where the JQ1-LY3023414 combination was synergistic at all 
concentrations tested. However, bromodomain inhibition did not sensitize RP-B-
01 cells to cisplatin treatment. This indicates that the therapeutic benefit 
associated with BET inhibition is specific to resistance induced upon PI3K 
targeted inhibition which is associated with the stabilization of MYC. 
 
On the other hand, when I tested a combination of LY3023414 and 
LY3214996, which target PI3K/mTOR and ERK1/2 respectively, I did not find 
synergy. Therefore, despite feedback ERK phosphorylation induced upon 
resistance, co-targeting ERK phosphorylation did not sensitize cells to treatment. 
This indicates a more central role for MYC in driving resistance. 
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A.5. Subtype distinct epigenetic signature predicts resistance to PI3K targeted 
inhibition  
Bladder cancer is a highly complex disease with high mutation burden 
that is only second to melanoma and lung cancer (Kim, Akbani et al. 2015). 
Although, we provided evidence that mutation status can predict response to 
treatment per see, we also think that other factors play a role such as molecular 
subtype. 
 
Therefore, using our comprehensive genomic and DNA methylathion 
data from our bladder cancer PDX models, we were able to show that R-B-01 
and RP-B-02 which are of basal-like and luminal-like subtype respectively have a 
distinct gene expression and DNA methylation profile. 
 
Interestingly, we found basal-like RP-B-01 to be enriched with DNA 
hypermethylation compared to luminal-like RP-B-02. It would be interesting to 
further study whether this behavior could be linked to the CpG Island Methylator 
Phenotype (CIMP) which was first described in colon cancer (Hughes, Melotte et 
al. 2013). 
 
In colon cancer, BET inhibition with JQ1 was found to preferentially inhibit 
the growth of a subset of epigenetically dysregulated colon cancer that exhibited 
the CIMP phenotype. Interestingly, this response in colon cancer was attributed 
to a distinct super enhancer region in CIMP positive colon cancer that regulates 
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MYC transcription (McCleland, Mesh et al. 2016). Therefore it would be 
interesting to know whether the therapeutic benefit we observed with JQ1 in 
basal-like RP-B-01 but not in RP-B-02 is linked to the hyper-methylator 
epigenetic signature we identified in this tumor. 
 
Moreover, we identified two mutually exclusive chromatin modifying 
mutations in RP-B-01 and RP-B-02 (KMT2D and KDM6A respectively). These 
two enzymes are involved with histone methylation and are thought to be 
subtype specific (Gui, Guo et al. 2011, Kim, Sharma et al. 2014, Network 2014). 
Yet it remains to be known, whether the distinct DNA CpG hypermethylation we 
found in RP-B-01 is linked to those mutations. 
 
Overall, we uncovered a distinct epigenetic signature for each model. 
DNA hypermethylation is a well characterized phenomenon in a multitude of 
cancers that is thought to be prognostically and therapeutically relevant (Hughes, 
Melotte et al. 2013). Although still controversial, therapeutic benefit associated 
with BET inhibition was shown to be linked to CIMP phenotype (McCleland, 
Mesh et al. 2016, Tögel, Nightingale et al. 2016). Therefore, herein we provide 
rationale for role of subtype specific-epigenetic signature in driving resistance to 
PI3K targeted inhibition in the context of distinct PIK3CA mutations. 
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B. Limitations of the Study 
This study provides proof of concept that PIK3CA mutation status is 
predictive of response to PI3K targeted inhibition. However, a key limiation of this 
study is that we used only two bladder cancer PDX models (RP-B-01 and RP-B-
02) in order to test treatment response in vivo.  However I am  currently in the 
process of developing further PDX models in order to validate our studies in vivo. 
I successfully developed and characterized 9 alternative bladder cancer PDX 
models that represent a wide range of histologies. As shown in Chapter IV 
(Figures 49, 50 and 51), I found two models (IU3T and IU5T) to be basal-like 
while 3 models (IU16T, IU80T and IU68T) to be luminal like. I screened for 
PIK3CA mutation status in those models and found IU68T to harbor a PIK3CA 
E545K mutation indicating that it behaves like RP-B-02 and thus would be a 
valuable tool to continue validation of our findings. 
 
Transfecting isogenic HEK cells with PIK3CA WT and mutants was key to 
determining the signficance of mutation status in predicting response to 
treatment. However, ideally another cell line would be important to strenghthen 
the validity of our findings. While HEK cells are readily transfectable and are well 
known for being used in wide range of settings to test the biological significance 
of various proteins (Thomas and Smart 2005, Nakanishi, Walter et al. 2016), it 
would be more physiologically relevant to use a urothelial cell line in order to 
monitor the oncogenic and therapeutic effect of HD PIK3CA mutations such as 
SV-HUC cells (Christian, Loretz et al. 1987). I tried to express PIK3CA 
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(WT/MUT) in SV-HUC cells however overexpression of PIK3CA in those cells, 
which naturally express high levels of PIK3CA and P-AKT, has been associated 
with inhibition of downstream AKT phosphorylation. Therefore, despite being 
physiologically relevant, SV-HUC cells were not optimal for testing the 
downstream effects of PIK3CA HD mutations. 
 
Another key limitation of the study is the lack of direct evidence regarding 
the mechanistic rationale behind the ability of PIK3CA E542K but not E545K 
mutation to drive distinct down stream signaling and drug interactions that play a 
role in therapeutic resistance. PIK3CA HD mutations are well established in the 
field to be RAS dependent. Yet, It is not clear whether interaction efficiency with 
RAS is distinct with each mutation in a manner that could influence feedback 
signaling. I did see therapeutic resistance with PIK3CA E542K but not the E545K 
mutation in addition to feedback activation of MAPK signaling in E542K mutant 
RP-B-01 but not in E545K mutant RP-B-02,. However I don’t currently have 
direct evidence to show that the RAS-MAPK activation that is specific to RP-B-01 
is mutation dependent. To test this possibility, ideally I would like to run a Co-IP 
experiment to examine whether RAS more strongly interact with PIK3CA E542K 
mutant protein in compariosn to its E545K mutant counterpart. Ultimately, this 
would provide stronger evidence that patients who carry the PIK3CA E542K 
mutation are more likey to develop resistance to PI3K targeted inhibition. 
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Additionally I was able to propose BET inhibition as an  additional tool 
that can be used in conjunction with PI3K targeted inhibition to overcome 
resistance to PI3K targted inhibition specifically in bladder cancer that harbors 
the PIK3CA E542K mutation. Although, I did study the epigenetic signature in 
each model, I was not able to identify so far a unique DNA hypermethylation 
signature in basal-like RP-B-01 that could provide a direct mechanistic rationale 
for the synergy between LY3023414-JQ1 combination in E542K mutant RP-B-01 
but not the E545K mutant RP-B-02. 
 
Taken together, this study provides a predictive paradigm for  mutation 
response to PI3K targeted inhibition in bladder cancer patients. Therefore, my 
stuidoes lay the foundation for better selection of pateint population on clinical 
trials, provide patients with more personalized treatment and therefore improved 
treatment outcome. 
 
C. Future directions 
This study lays the foundation for molecularly driven patient selection on 
bladder cancer clinical trials testing PI3K targeted therapy. Further future studies 
are needed to strengthen the mechanistic rationale behind this predictive model 
and to provide more solid evidence for future clinical trial design. 
 
While our in silico predictive analysis of drug-PI3K interaction showed 
that PIK3CA E545K mutation is associated with more stable binding with 
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LY3023414 compared to the PIK3CA E542K mutation, ideally we would like to 
run surface plasmon resonance spectroscopy (SPR) (Patching 2014) in order to 
calculate association ('on rate', ka) and dissociation rates ('off rate', kd), the 
equilibrium dissociation constant ('binding constant', KD) for LY3023414 in the 
context of each distinct PIK3CA mutations. We expect that LY3023414 will have 
faster dissociative off rate (Koff) in the presence of the E542K mutated PIK3CA 
protein; suggesting a shorter drug residence time and weaker inhibitory effect. 
Ultimately, this would strengthen our MDS studies and provide a potential 
mechanism underlying the therapeutic resistance in tumors harboring the E542K 
mutation compared to those harboring the E545K mutation. 
 
As previously mentioned, ideally we would like to validate our mutation 
dependent drug response data in alternative cell lines. We believe that 
immortalized urothelial cells (SV-HUCs) are ideal for that purpose since they are 
physiologically relevant. They could also provide a tool for testing the differential 
effect of mutation not only on drug response but also cell proliferation, 
morphology and migration/invasion. 
 
Further PIK3CA mutant bladder cancer PDX models should be tested for 
mutation-induced drug response in the context of distinct subtype (i.e. basal vs 
luminal). If it is not feasible to develop a suitable number of PDX models in order 
to adequately power our studies, an alternative tool would be to use CRISPR-
CAS-HDR system  (Liang, Potter et al. 2017) to edit the mutation in RP-B-01 
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from PIK3CA E542K to PIK3CA E545K mutation. Then we would test whether 
mutation change would be associated with reversal of therapeutic resistance. 
This would provide powerful evidence that treatment response is indeed mutation 
dependent. 
 
The complexity of bladder cancer as well as determinants of therapeutic 
response compelled us to look at the role of epigenetic changes in driving drug 
resistance. Thus in the future we would like to investigate this hypothesis in more 
depth. The epigenetic/DNA methylome signature of bladder cancer would 
potentially provide a more mechanistic rationale for the synergy we observed 
between JQ1 and LY3023414.  Similar to the DNA hypermethylation signature 
we found in RP-B-01; hypermethylator phenotype has been proposed in other 
tumors, such as colon cancer (Issa 2003, Barault, Charon-Barra et al. 2008, 
Irizarry, Ladd-Acosta et al. 2009, Sánchez-Carbayo 2012). In colon cancer, it was 
shown that in association with DNA hypermethylation, MYC is activated through 
super enhancers. In this context bromodomain inhibition (JQ1) was indeed very 
beneficial and capable of curbing tumor growth (McCleland, Mesh et al. 2016). 
Therefore, it would be interesting to see if a similar signature is associated with 
the benefit associated with bromodomain inhibition in bladder cancer. 
 
Overall, this study provides an unprecedented paradigm for prediction of 
treatment response to PI3K targeted inhibition in MIBC. Cross talk between hot 
spot PIK3CA mutation and tumor subtype has been investigated for its role in 
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therapeutic response/resistance. The future goal of this piece of work is to 
provide mechanistic rationale for better clinical trial design in a disease where an 
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Graduate Research Assistant – Department of Pharmacology and 
Toxicology, Indiana University School of Medicine, Indianapolis, IN - 
August 2015 – December 2018 
 
Graduate Research Assistant – Department of Pharmacology and 
Molecular Cancer Therapeutics, Roswell Park Cancer Institute, Buffalo, 
NY- August 2013 – August 2015 
 
Resident Doctor – Department of Clinical Oncology and Nuclear 
Medicine, Mansoura University, Mansoura, Egypt - October 2008 - July 
2012 
 
General Practitioner – Al-Montazah Primary Healthcare unit- Egyptian 
Department of Health, New Damietta, Egypt- March 2008 - October 2008 
 
Medical Intern (Transitional Internship Year-PGY1) – Demerdash 




PhD Candidate – Supervisor: Professor. Dr.  Roberto Pili 
Department of Pharmacology and Toxicology – IU Simon Cancer Center , 
Department of Hematology/Oncology, Indiana University School of 
Medicine, Indianapolis, IN - August 2015 – December 2018 
Research Focus: 
 
 Drug Development in Bladder cancer management (Mechanisms of 
resistance to PI3K targeted therapy in bladder cancer- in 
collaboration with Lilly) 
 Development of antibodies that target tumor associated 
macrophages (+/- androgen blockade therapy) in the management 
of prostate cancer-in collaboration with Syndax 
 Diet studies in syngeneic mice models of various GU malignancies 
(prostate/Renal) to study the effect of diet on enhancing the 
therapeutic efficiency of immunotherapies 
 
Graduate Research Assistant – Supervisor: Assistant. Professor. 
Hannelore Heemers 
Department of Pharmacology and Molecular Cancer Therapeutics, 
Roswell Park Cancer Institute, Buffalo, NY- December 2013 – April 2014 
Research Focus: 
 Validate the role of serum response factor in driving resistance to 
Androgen Deprivation Therapy in prostate cancer cell lines. 
 
Graduate Research Assistant – Supervisor: Professor. Candace 
Johnson  
Department of Pharmacology and Molecular Cancer Therapeutics, 
Roswell Park Cancer Institute, Buffalo, NY- July 2013 – December 2013 
Research Focus: 
 
 Study the role of Vitamin D in sensitizing bladder cancer cell lines 
to cisplatin treatment.  
 
Research Assistant – Supervisor: Professor. Sibylle Mittnacht 
University College London, London, UK – July 2012 - July 2013 
Research Focus: 
 Validation of Ki-67 as a clinically applicable readout for the 
synergistic combination of PD-0332991 with crizotinib in the 
treatment of a panel of cancer cell lines 
 
Research Assistant – Supervisor: Professor. Hanem Sakr  
Department of Clinical Oncology and Nuclear Medicine, Faculty of 
Medicine, Mansoura, Egypt – October 2008 – April 2012 
Research Focus: 
 Retrospective literature Review - Problems In Pediatric Tumors 




Mentoring masters and summer rotation students. Department of 
Pharmacology and Toxicology, Indiana University School of Medicine, 
Indianapolis, IN – August 2015 – December 2018 
Techniques taught: 
 
 In vivo mouse models handling 
 Molecular Biology Techniques (Western Blotting, qPCR) 
 Immunohistochemistry 
 In vitro tissue culture training 
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bladder cancer (2019). Molecular cancer therapeutics. (Under 
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 Orillion, A., Damayanti, N., Shen, L.,…, Elbanna, M., ….., and Pili,R. 
(2018). Dietary protein restriction reprograms tumor associated 
macrophages and enhances immunotherapy. Clinical Cancer Research, 
24(24): p. 6383-6395. 
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response to cisplatin treatment but not to PI3K inhibition in bladder cancer 
patient-derived xenografts. Oncotarget, 7(47), 76374., 2015, 58, 5015-
5027 
 Elbanna, M., & Heemers, H. V. (2014). Alternative approaches to prevent 




 Elbanna, M., Damayanti,N., Chintala,S., Pili.,R.. PIK3CA E542K mutation 
in bladder cancer confers resistance to PI3K targeted therapy but synergy 
with BET inhibition. Proceedings of the American Association for Cancer 
Research Annual Meeting 2018. 2018, Jul; 78(13 Suppl): Abstract nr 
1825. 
 Elbanna, M., Chintala, S., Ciamporcero, E., Adelayie, R., Orillion, A., 
Arisa, S., ... & Pili, R. (2017). In vitro modeling of patient derived bladder 
 
cancer cell lines in 3D culture systems [abstract]. Proceedings of the 
American Association for Cancer Research Annual Meeting 2017; 2017 
Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017; 
77(13 Suppl): Abstract nr 5783.  
 Elbanna, M., Ciamporcero, E., Adelaiye, R., Orillion, A., Chintala, S., & 
Pili, R. (2016). Differential response to a dual PI3K/mTOR inhibitor in 
PIK3CA mutant urothelial cancer patient derived xenografts. [abstract]. In: 
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POSTER PRESENTATIONS 
 Elbanna, M., Chintala, S., Ciamporcero, E., ... & Pili (2017).Understanding 
epigenetic determinants of response to PI3K targeted therapy in PIK3CA 
driven bladder cancer.  Poster presented at IU Cancer Research Day 
2017.  Best poster award (4th Place), Basic Science section. 
 
 Elbanna, M., Chintala, S., Ciamporcero, E., Adelayie, R., Orillion, A., 
Arisa, S., ... & Fishel, M. In vitro modeling of patient derived bladder 
cancer cell lines in 3D culture systems (2017). Poster presented at AACR 
2017.  Best 3D culture poster award, Corning. 
 Elbanna, M., Ciamporcero, E., Adelaiye, R., Orillion, A., Chintala, S., & 
Pili, R. (2016).  Differential response to a dual PI3K/mTOR inhibitor in 
PIK3CA mutant urothelial cancer patient derived xenografts. Poster 
presented at AACR 2016 and IU Cancer Research Day 2016.  Best 
Poster award (3rd Place), translational Science Section 
 Elbanna, M., Ciamporcero, E., Ramakrishnan, S., Adelaiye, R., Shen, L., 
Orillion, A., ... & Pili, R. (2015). Characterization of patient-derived bladder 
cancer xenografts: role of xCT in response to cisplatin. Poster presented 
at AACR 2015. 
 
ORAL PRESENTATIONS 
 Elbanna, M. (July 2017). Differential response to a dual PI3K/mTOR 
inhibitor in PI3KCA mutant urothelial cancer patient derived xenografts. 
Indiana Basic Urologic Research (IBUR) meeting. Indianapolis, IN. 
 Elbanna, M. (October 2016).  Understanding resistance to PI3K targeted 
therapy in bladder cancer Management.  MD Anderson Cancer Center. 
”Symposium on Cancer Evolution: Mechanisms of Vulnerability and 
Resistance.”  Houston, TX.  
 
 Elbanna, M. (October 2014). Student Seminar presentation. Paper 
discussion:  Rebouissou, S., et al. (2014). "EGFR as a potential 
therapeutic target for a subset of muscle-invasive bladder cancers 
presenting a basal-like phenotype." Science translational medicine 6(244): 
244ra291-244ra291. Roswell Park Cancer Institute, Buffalo, NY. 
 Elbanna, M. (March 2014). Student Seminar presentation. Paper 
discussion:  Korpal, M., et al. (2013). "An F876L mutation in androgen 
receptor confers genetic and phenotypic resistance to MDV3100 
(enzalutamide)." Cancer discovery 3(9): 1030-1043. Roswell Park Cancer 
Institute, Buffalo, NY. 
 
PROFESSIONAL MEMBERSHIPS 
2014- Present Member, The American Association of Cancer 
Research (AACR) 
2014- Present Member, The American Society of Clinical Oncology 
(ASCO) 
2007-Present  Member, Egyptian Medical Syndicate (EMS) 
 
FELLOWSHIPS AND AWARDS 
 Paradise Travel Award-  Department of Pharmacology and Toxicology, 
IUSM- January 2018 
 Best Poster Award- IU Cancer Research Day (3rd  place, Translational 
science section)- May 2018 
 
 Best Poster Award- IU Cancer Research Day (4th place, Basic science 
section)- May 2017  
 Fulbright Foreign student Award- Fellowship to conduct doctoral 
research in the United States- August 2013-2016 
 O’Brien Fellowship for biological microscopy (IU)- Fellowship towards 
training and free usage of IU confocal microscopy facilities for imaging of 
3D culture developed for Bladder cancer- July2016-2018       
 Nominated by IU for the HHMI pre-doctoral Award- November 2016 
 Young Investigator Travel Fellowship- MD Anderson Cancer Center.  
”Symposium on Cancer Evolution: Mechanisms of Vulnerability and 
Resistance” Houston, TX- October 2016 
 Best Poster Award Best Poster Award- IU Cancer Research Day (3rd 
place, translational science section)- May 2016 
 University College London-Global Excellence Award- Award for MSc 
Degree tuition expenses- August 2012-2013 
 Arab-British Chamber Charitable Foundation (ABCCF) Bursary- 
Award for MSc Degree tuition expenses- August 2012-2013 
 Certificate of excellence as Intern/PGY1-  Department of Pediatrics; 
Neonatology Division, Ain Shams university, Cairo, Egypt- May 2008 
 Fellowship from the International Federation of Medical Students 
Associations (IFMSA)- to conduct clinical clerkship training in 
Department of Ophthalmology, Oviedo, Spain- August 2004 
 
 Fellowship from the International Federation of Medical Students 
Associations (IFMSA)- to conduct clinical clerkship training in 
Department of Pediatrics, Pisa, Italy- July 2003 
 
EXTRACURRICULAR ACTIVITIES 
Volunteer translator at Dar Al Tarjama- March 2007- September 2008  
 An initiative concerned with translating remarkable Arabic works 
to English and vice versa as means of mutual cultural 
understanding. 
 
Volunteer at Bridges foundation- March 2007- September 2008   
 An initiative concerned with creating bridges between nations 
through outreach workshops and cultural events. 
 I volunteered in organization of workshops and in translating their 
website into French. 
 
Volunteer in the organization of the Arab universities' youth week 
held in Mansoura University, Egypt- January 2006  
 
Volunteer in the organization of the Egyptian universities' youth 
week held in Mansoura University, Egypt- January 2005  
  
 
COMMUNITY SERVICES AND OUTREACH PROGRAMS 
Fund raising in department of clinical oncology, Mansoura University 
Hospitals, Mansoura, Egypt- April 2011  
 Fundraising was initiated for buying new treatment chairs in the 
outpatient chemotherapy unit and buying a new Gamma camera 
at our center) 
 
Outreach cancer screening campaign, Mansoura University 
Hospitals, Mansoura, Egypt- January 2010  
 Arranged by the faculty of medicine,  Mansoura university (Egypt) 
in ''Meniet Elnasr; rural region in our province'' 
 
Volunteer at the ''Dakahliya Cancer Patients' Association'', 
Mansoura, Egypt- October 2008-2012 
 Responsibilities: One on one assessment of individual cancer 
cases that need financial and/or psychological support. 
 
Volunteer at ''Mazeed Charitable Organization'', Cairo, Egypt- March 
2007- 2008 
 Concerned with providing financial and social support for the less 




Outreach medical campaign, faculty of medicine, Mansoura 
University – Mansoura, Egypt- March 2006  
 The campaign offered primary medical care to border regions in 
southern Egypt (Marsa Alam, Halayeb and Shalateen) 
